C:\Program Files\Stnexp\Queries\10761977



chain nodes :
42 43 45 49 50 52 53 54 55 56 57 67 68
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
22 23 24 25 28 31 34
ring/chain nodes :
59 60 61 62 63 64 69 70 71 72
chain bonds :
2-49 4-59 4-69 5-50 9-52 10-60 10-70 12-53 14-54 16-61 16-71
18-55 21-56 22-62 22-72 23-57 42-43 43-63 43-67 43-68
ring bonds :
1-2 1-6 2-3 3-4 3-25 4-5 5-6 6-25 7-8 7-12 8-9 8-28 9-10 10-11
11-12 11-28 13-14 13-18 14-15 15-16 15-31 16-17 17-18 17-31 19-20
19-24 20-21 20-34 21-22 22-23 23-24 24-34
exact/norm bonds :
2-49 4-5 4-69 5-50 9-52 10-11 10-70 12-53 14-54 15-31 16-17
16-71 17-31 18-55 20-34 21-56 22-23 22-72 23-57 24-34 42-43 43-67
43-68
exact bonds :
1-2 1-6 2-3 3-4 3-25 4-59 5-6 6-25 7-8 7-12 8-9 8-28 9-10
10-60 11-12 11-28 13-14 13-18 14-15 15-16 16-61 17-18 19-20 19-24
20-21 21-22 22-62 23-24 43-63
isolated ring systems :
containing 1 : 7 : 13 : 19 :

G1:[*1],[*2],[*3],[*4]

G2:H,[*5]

G3:H,[*6]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom

```
            11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom
    18:Atom  19:Atom  20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom
    28:Atom  31:Atom  34:Atom  42:CLASS  43:CLASS  45:CLASS  49:CLASS  50:CLASS
    52:CLASS  53:CLASS  54:CLASS  55:CLASS  56:CLASS  57:CLASS  59:CLASS
    60:CLASS  61:CLASS  62:CLASS  63:CLASS  64:CLASS  67:CLASS  68:CLASS
    69:CLASS  70:CLASS  71:CLASS  72:CLASS
Generic attributes :
    45:
    Saturation              : Saturated
    Number of Carbon Atoms : less than 7

Element Count :
    Node 45: Limited
        C,C1-6
```

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839

L3 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L4 SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10761977 (species).str



chain nodes :
42 43
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 28 31 34
ring/chain nodes :
44
chain bonds :
42-43 43-44
ring bonds :
1-2 1-6 2-3 3-4 3-25 4-5 5-6 6-25 7-8 7-12 8-9 8-28 9-10 10-11 11-12
11-28 13-14 13-18 14-15 15-16 15-31 16-17 17-18 17-31 19-20 19-24 20-21
20-34 21-22 22-23 23-24 24-34

```
exact/norm bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  13-14  13-18
14-15  15-16  15-31  16-17  17-18  17-31  19-20  19-24  20-21  20-34  21-22  22-23
23-24  24-34  42-43
exact bonds :
3-25  6-25  8-28  11-28  43-44
isolated ring systems :
containing 1 : 7 : 13 : 19 :


G1:[*1],[*2],[*3],[*4]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  28:Atom  31:Atom  34:Atom
42:CLASS  43:CLASS  44:CLASS



L5      STRUCTURE UPLOADED

=> que L5 AND L3 NOT L4

L6   QUE L5 AND L3 NOT L4

=> d l6
L6 HAS NO ANSWERS
L3              SCR 1839
L4              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L5              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L6              QUE  L5 AND L3 NOT L4


=> s l6 sss sam
SAMPLE SEARCH INITIATED 17:19:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  81051 TO ITERATE

  1.2% PROCESSED    1000 ITERATIONS                                  6 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      EXCEEDS 1000000
PROJECTED ANSWERS:         EXCEEDS    8403

L7            6 SEA SSS SAM L5 AND L3 NOT L4

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end
```

=> screen 1839

L8 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L9 SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10761977 (sp 1).str







chain nodes :
42 43
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 28 31 34 44 46 47 48 49 50
chain bonds :
42-43 43-44
ring bonds :
1-2 1-6 2-3 3-4 3-25 4-5 5-6 6-25 7-8 7-12 8-9 8-28 9-10 10-11 11-12
11-28 13-14 13-18 14-15 15-16 15-31 16-17 17-18 17-31 19-20 19-24 20-21
20-34 21-22 22-23 23-24 24-34 44-46 44-50 46-47 47-48 48-49 49-50
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 15-31 16-17 17-18 17-31 19-20 19-24 20-21 20-34 21-22 22-23
23-24 24-34 42-43

```
exact bonds :
3-25  6-25  8-28  11-28  43-44
normalized bonds :
44-46  44-50  46-47  47-48  48-49  49-50
isolated ring systems :
containing 1 : 7 : 13 : 19 :


G1:[*1],[*2],[*3],[*4]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  28:Atom  31:Atom  34:Atom
42:CLASS  43:CLASS  44:CLASS  46:Atom  47:Atom  48:Atom  49:Atom  50:Atom



L10     STRUCTURE UPLOADED

=> que L10 AND L8 NOT L9

L11  QUE L10 AND L8 NOT L9

=> d l11
L11 HAS NO ANSWERS
L8              SCR 1839
L9              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L10             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L11             QUE  L10 AND L8 NOT L9


=> s l11 sss sam
SAMPLE SEARCH INITIATED 17:21:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  50419 TO ITERATE

  2.0% PROCESSED    1000 ITERATIONS                                  6 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:       994990 TO  1021770
PROJECTED ANSWERS:            5007 TO     7093

L12           6 SEA SSS SAM L10 AND L8 NOT L9

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839
```

L13 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L14 SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10761977 (sp 2).str



chain nodes :
42 43 51 55 56 58 59 60 61 62 63
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 28 31 34 44 46 47 48 49 50
chain bonds :
2-55 5-56 9-58 12-59 14-60 18-61 21-62 23-63 42-43 43-44
ring bonds :
1-2 1-6 2-3 3-4 3-25 4-5 5-6 6-25 7-8 7-12 8-9 8-28 9-10 10-11 11-12 11-28 13-14 13-18 14-15 15-16 15-31 16-17 17-18 17-31 19-20 19-24 20-21 20-34 21-22 22-23 23-24 24-34 44-46 44-50 46-47 47-48 48-49 49-50
exact/norm bonds :
1-2 1-6 2-3 2-55 3-4 4-5 5-6 5-56 7-8 7-12 8-9 9-10 9-58 10-11 11-12 12-59 13-14 13-18 14-15 14-60 15-16 15-31 16-17 17-18 17-31 18-61 19-20 19-24 20-21 20-34 21-22 21-62 22-23 23-24 23-63 24-34 42-43
exact bonds :
3-25 6-25 8-28 11-28 43-44
normalized bonds :
44-46 44-50 46-47 47-48 48-49 49-50
isolated ring systems :

containing 1 : 7 : 13 : 19 :

G1:[*1],[*2],[*3],[*4]

G2:H,[*5]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 28:Atom 31:Atom 34:Atom
42:CLASS 43:CLASS 44:CLASS 46:Atom 47:Atom 48:Atom 49:Atom 50:Atom 51:CLASS
55:CLASS 56:CLASS 58:CLASS 59:CLASS 60:CLASS 61:CLASS 62:CLASS 63:CLASS
Generic attributes :
51:
Saturation : Saturated
Number of Carbon Atoms : less than 7

Element Count :
Node 51: Limited
C,C1-6

L15 STRUCTURE UPLOADED

=> que L15 AND L13 NOT L14

L16 QUE L15 AND L13 NOT L14

=> d l16
L16 HAS NO ANSWERS
L13 SCR 1839
L14 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L15 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L16 QUE L15 AND L13 NOT L14

=> s l16 sss sam
SAMPLE SEARCH INITIATED 17:26:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 50419 TO ITERATE

2.0% PROCESSED 1000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 994990 TO 1021770
PROJECTED ANSWERS: 2288 TO 3762

L17 3 SEA SSS SAM L15 AND L13 NOT L14

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839

L18 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L19 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10761977 (sp 3).str







chain nodes :
42 43 51 55 56 58 59 60 61 62 63
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 28 31 34 44 46 47 48 49 50 65 66 67 68 69 70 71 72 73 74
75 76 77 78 79 80 81 82 83 84 85 86 87 88

```
chain bonds :
2-55  4-65  5-56  9-58  10-71  12-59  14-60  16-77  18-61  21-62  22-83  23-63
42-43  43-44
ring bonds :
1-2  1-6  2-3  3-4  3-25  4-5  5-6  6-25  7-8  7-12  8-9  8-28  9-10  10-11  11-12
11-28  13-14  13-18  14-15  15-16  15-31  16-17  17-18  17-31  19-20  19-24  20-21
20-34  21-22  22-23  23-24  24-34  44-46  44-50  46-47  47-48  48-49  49-50  65-66
65-70  66-67  67-68  68-69  69-70  71-72  71-76  72-73  73-74  74-75  75-76  77-78
77-82  78-79  79-80  80-81  81-82  83-84  83-88  84-85  85-86  86-87  87-88
exact/norm bonds :
1-2  1-6  2-3  2-55  3-4  4-5  5-6  5-56  7-8  7-12  8-9  9-10  9-58  10-11  11-12
12-59  13-14  13-18  14-15  14-60  15-16  15-31  16-17  17-18  17-31  18-61  19-20
19-24  20-21  20-34  21-22  21-62  22-23  23-24  23-63  24-34  42-43
exact bonds :
3-25  4-65  6-25  8-28  10-71  11-28  16-77  22-83  43-44
normalized bonds :
44-46  44-50  46-47  47-48  48-49  49-50  65-66  65-70  66-67  67-68  68-69  69-70
71-72  71-76  72-73  73-74  74-75  75-76  77-78  77-82  78-79  79-80  80-81  81-82
83-84  83-88  84-85  85-86  86-87  87-88
isolated ring systems :
containing 1 : 7 : 13 : 19 :


G1:[*1],[*2],[*3],[*4]

G2:H,[*5]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  28:Atom  31:Atom  34:Atom
42:CLASS  43:CLASS  44:CLASS  46:Atom  47:Atom  48:Atom  49:Atom  50:Atom  51:CLASS
 55:CLASS  56:CLASS  58:CLASS  59:CLASS  60:CLASS  61:CLASS  62:CLASS  63:CLASS
65:Atom  66:Atom  67:Atom  68:Atom  69:Atom  70:Atom  71:Atom  72:Atom  73:Atom
74:Atom  75:Atom  76:Atom  77:Atom  78:Atom  79:Atom  80:Atom  81:Atom  82:Atom
83:Atom  84:Atom  85:Atom  86:Atom  87:Atom  88:Atom
Generic attributes :
51:
Saturation              : Saturated
Number of Carbon Atoms : less than 7

Element Count :
Node 51: Limited
    C,C1-6




L20     STRUCTURE UPLOADED

=> que L20 AND L18 NOT L19

L21  QUE L20 AND L18 NOT L19

=> d l21
L21 HAS NO ANSWERS
```

```
L18             SCR 1839
L19             SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L20             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L21             QUE  L20 AND L18 NOT L19


=> s l21 sss sam
SAMPLE SEARCH INITIATED 17:31:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   3336 TO ITERATE

 30.0% PROCESSED    1000 ITERATIONS                                3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        63256 TO    70184
PROJECTED ANSWERS:              11 TO      389

L22           3 SEA SSS SAM L20 AND L18 NOT L19

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L23   SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L24   SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10761977 (sp 4).str
```



chain nodes :
42 43 51 55 56 58 59 60 61 62 63
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 28 31 34 44 46 47 48 49 50
ring/chain nodes :
65 66 67 68
chain bonds :
2-55 4-65 5-56 9-58 10-66 12-59 14-60 16-67 18-61 21-62 22-68 23-63
42-43 43-44
ring bonds :
1-2 1-6 2-3 3-4 3-25 4-5 5-6 6-25 7-8 7-12 8-9 8-28 9-10 10-11 11-12
11-28 13-14 13-18 14-15 15-16 15-31 16-17 17-18 17-31 19-20 19-24 20-21
20-34 21-22 22-23 23-24 24-34 44-46 44-50 46-47 47-48 48-49 49-50
exact/norm bonds :
1-2 1-6 2-3 2-55 3-4 4-5 5-6 5-56 7-8 7-12 8-9 9-10 9-58 10-11 11-12
12-59 13-14 13-18 14-15 14-60 15-16 15-31 16-17 17-18 17-31 18-61 19-20
19-24 20-21 20-34 21-22 21-62 22-23 23-24 23-63 24-34 42-43
exact bonds :
3-25 4-65 6-25 8-28 10-66 11-28 16-67 22-68 43-44
normalized bonds :
44-46 44-50 46-47 47-48 48-49 49-50
isolated ring systems :
containing 1 : 7 : 13 : 19 :

G1:[*1],[*2],[*3],[*4]

```
G2:H,[*5]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  28:Atom  31:Atom  34:Atom
42:CLASS  43:CLASS  44:CLASS  46:Atom  47:Atom  48:Atom  49:Atom  50:Atom  51:CLASS
 55:CLASS  56:CLASS  58:CLASS  59:CLASS  60:CLASS  61:CLASS  62:CLASS  63:CLASS
65:CLASS  66:CLASS  67:CLASS  68:CLASS
Generic attributes :
51:
Saturation              : Saturated
Number of Carbon Atoms : less than 7

Element Count :
Node 51: Limited
    C,C1-6




L25     STRUCTURE UPLOADED

=> que L25 AND L23 NOT L24

L26  QUE L25 AND L23 NOT L24

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L27   SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L28   SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10761977 (sp 4).str
```







chain nodes :
42 43 51 55 56 58 59 60 61 62 63
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 28 31 34 44 46 47 48 49 50
ring/chain nodes :
65 66 67 68
chain bonds :
2-55 4-65 5-56 9-58 10-66 12-59 14-60 16-67 18-61 21-62 22-68 23-63
42-43 43-44
ring bonds :
1-2 1-6 2-3 3-4 3-25 4-5 5-6 6-25 7-8 7-12 8-9 8-28 9-10 10-11 11-12
11-28 13-14 13-18 14-15 15-16 15-31 16-17 17-18 17-31 19-20 19-24 20-21
20-34 21-22 22-23 23-24 24-34 44-46 44-50 46-47 47-48 48-49 49-50
exact/norm bonds :
1-2 1-6 2-3 2-55 3-4 4-5 5-6 5-56 7-8 7-12 8-9 9-10 9-58 10-11 11-12
12-59 13-14 13-18 14-15 14-60 15-16 15-31 16-17 17-18 17-31 18-61 19-20
19-24 20-21 20-34 21-22 21-62 22-23 23-24 23-63 24-34 42-43
exact bonds :
3-25 4-65 6-25 8-28 10-66 11-28 16-67 22-68 43-44
normalized bonds :
44-46 44-50 46-47 47-48 48-49 49-50
isolated ring systems :
containing 1 : 7 : 13 : 19 :

G1:[*1],[*2],[*3],[*4]

```
G2:H,[*5]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  28:Atom  31:Atom  34:Atom
42:CLASS  43:CLASS  44:CLASS  46:Atom  47:Atom  48:Atom  49:Atom  50:Atom  51:CLASS
 55:CLASS  56:CLASS  58:CLASS  59:CLASS  60:CLASS  61:CLASS  62:CLASS  63:CLASS
65:CLASS  66:CLASS  67:CLASS  68:CLASS
Generic attributes :
51:
Saturation             : Saturated
Number of Carbon Atoms : less than 7

Element Count :
Node 51: Limited
    C,C1-6




L29     STRUCTURE UPLOADED

=> que L29 AND L27 NOT L28

L30  QUE L29 AND L27 NOT L28

=> d l30
L30 HAS NO ANSWERS
L27             SCR 1839
L28             SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L29             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L30             QUE  L29 AND L27 NOT L28


=> s l30 sss sam
SAMPLE SEARCH INITIATED 17:34:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  11494 TO ITERATE

  8.7% PROCESSED    1000 ITERATIONS                                3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       223457 TO   236303
PROJECTED ANSWERS:             337 TO     1041

L31           3 SEA SSS SAM L29 AND L27 NOT L28

=> => ....Testing the current file.... screen
```

```
ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839

L32   SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L33   SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10761977 (sp 5).str
```







```
chain nodes :
42  43  45  49  50  52  53  54  55  56  57  67  68
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23
24  25  28  31  34
ring/chain nodes :
59  60  61  62  63  64
chain bonds :
2-49  4-59  5-50  9-52  10-60  12-53  14-54  16-61  18-55  21-56  22-62  23-57
42-43  43-63  43-67  43-68
ring bonds :
1-2  1-6  2-3  3-4  3-25  4-5  5-6  6-25  7-8  7-12  8-9  8-28  9-10  10-11  11-12
11-28  13-14  13-18  14-15  15-16  15-31  16-17  17-18  17-31  19-20  19-24  20-21
20-34  21-22  22-23  23-24  24-34
exact/norm bonds :
1-2  1-6  2-3  2-49  3-4  4-5  5-6  5-50  7-8  7-12  8-9  9-10  9-52  10-11  11-12
12-53  13-14  13-18  14-15  14-54  15-16  15-31  16-17  17-18  17-31  18-55  19-20
19-24  20-21  20-34  21-22  21-56  22-23  23-24  23-57  24-34  42-43  43-67  43-68
```

```
exact bonds :
3-25  4-59  6-25  8-28  10-60  11-28  16-61  22-62  43-63
isolated ring systems :
containing 1 : 7 : 13 : 19 :


G1:[*1],[*2],[*3],[*4]

G2:H,[*5]

G3:H,[*6]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  28:Atom  31:Atom  34:Atom
42:CLASS  43:CLASS  45:CLASS  49:CLASS  50:CLASS  52:CLASS  53:CLASS  54:CLASS
55:CLASS  56:CLASS  57:CLASS  59:CLASS  60:CLASS  61:CLASS  62:CLASS  63:CLASS
64:CLASS  67:CLASS  68:CLASS
Generic attributes :
45:
Saturation              : Saturated
Number of Carbon Atoms : less than 7

Element Count :
Node 45: Limited
    C,C1-6




L34     STRUCTURE UPLOADED

=> que L34 AND L32 NOT L33

L35  QUE L34 AND L32 NOT L33

=> d l35
L35 HAS NO ANSWERS
L32             SCR 1839
L33             SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L34             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L35             QUE  L34 AND L32 NOT L33


=> s l35 sss sam
SAMPLE SEARCH INITIATED 17:39:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  22588 TO ITERATE

  4.4% PROCESSED    1000 ITERATIONS                                3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       442768 TO   460752
PROJECTED ANSWERS:             862 TO     1848

L36           3 SEA SSS SAM L34 AND L32 NOT L33

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L37   SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L38   SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10761977 (sp 6).str
```







```
chain nodes :
42  43  45  49  50  52  53  54  55  56  57  67  68
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23
24  25  28  31  34
ring/chain nodes :
59  60  61  62  63  64  69  70  71  72
chain bonds :
```

```
2-49  4-59  4-69  5-50  9-52  10-60  10-70  12-53  14-54  16-61  16-71  18-55
21-56  22-62  22-72  23-57  42-43  43-63  43-67  43-68
ring bonds :
1-2  1-6  2-3  3-4  3-25  4-5  5-6  6-25  7-8  7-12  8-9  8-28  9-10  10-11  11-12
11-28  13-14  13-18  14-15  15-16  15-31  16-17  17-18  17-31  19-20  19-24  20-21
20-34  21-22  22-23  23-24  24-34
exact/norm bonds :
1-2  1-6  2-3  2-49  3-4  4-5  4-69  5-6  5-50  7-8  7-12  8-9  9-10  9-52  10-11
10-70  11-12  12-53  13-14  13-18  14-15  14-54  15-16  15-31  16-17  16-71  17-18
17-31  18-55  19-20  19-24  20-21  20-34  21-22  21-56  22-23  22-72  23-24  23-57
24-34  42-43  43-67  43-68
exact bonds :
3-25  4-59  6-25  8-28  10-60  11-28  16-61  22-62  43-63
isolated ring systems :
containing 1 : 7 : 13 : 19 :


G1:[*1],[*2],[*3],[*4]

G2:H,[*5]

G3:H,[*6]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  28:Atom  31:Atom  34:Atom
42:CLASS  43:CLASS  45:CLASS  49:CLASS  50:CLASS  52:CLASS  53:CLASS  54:CLASS
55:CLASS  56:CLASS  57:CLASS  59:CLASS  60:CLASS  61:CLASS  62:CLASS  63:CLASS
64:CLASS  67:CLASS  68:CLASS  69:CLASS  70:CLASS  71:CLASS  72:CLASS
Generic attributes :
45:
Saturation              : Saturated
Number of Carbon Atoms : less than 7

Element Count :
Node 45: Limited
    C,C1-6




L39     STRUCTURE UPLOADED

=> que L39 AND L37 NOT L38

L40  QUE L39 AND L37 NOT L38

=> d 140
L40 HAS NO ANSWERS
L37             SCR 1839
L38             SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L39             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *
```

```
Structure attributes must be viewed using STN Express query preparation.
L40             QUE  L39 AND L37 NOT L38


=> s l40 sss sam
SAMPLE SEARCH INITIATED 17:43:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  22588 TO ITERATE

  4.4% PROCESSED    1000 ITERATIONS                                 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       442768 TO   460752
PROJECTED ANSWERS:             166 TO      736

L41           1 SEA SSS SAM L39 AND L37 NOT L38

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L42   SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L43   SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10761977 (sp 7).str
```



chain nodes :
42 43 45 49 50 52 53 54 55 56 57 67 68
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 28 31 34
ring/chain nodes :
59 60 61 62 63 64 69 70 71 72
chain bonds :
2-49 4-59 4-69 5-50 9-52 10-60 10-70 12-53 14-54 16-61 16-71 18-55
21-56 22-62 22-72 23-57 42-43 43-63 43-67 43-68
ring bonds :
1-2 1-6 2-3 3-4 3-25 4-5 5-6 6-25 7-8 7-12 8-9 8-28 9-10 10-11 11-12
11-28 13-14 13-18 14-15 15-16 15-31 16-17 17-18 17-31 19-20 19-24 20-21
20-34 21-22 22-23 23-24 24-34
exact/norm bonds :
2-49 4-5 4-69 5-50 9-52 10-11 10-70 12-53 14-54 15-31 16-17 16-71 17-31
18-55 20-34 21-56 22-23 22-72 23-57 24-34 42-43 43-67 43-68
exact bonds :
1-2 1-6 2-3 3-4 3-25 4-59 5-6 6-25 7-8 7-12 8-9 8-28 9-10 10-60 11-12
11-28 13-14 13-18 14-15 15-16 16-61 17-18 19-20 19-24 20-21 21-22 22-62
23-24 43-63
isolated ring systems :
containing 1 : 7 : 13 : 19 :

G1:[*1],[*2],[*3],[*4]

G2:H,[*5]

G3:H,[*6]

```
Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  28:Atom  31:Atom  34:Atom
42:CLASS  43:CLASS  45:CLASS  49:CLASS  50:CLASS  52:CLASS  53:CLASS  54:CLASS
55:CLASS  56:CLASS  57:CLASS  59:CLASS  60:CLASS  61:CLASS  62:CLASS  63:CLASS
64:CLASS  67:CLASS  68:CLASS  69:CLASS  70:CLASS  71:CLASS  72:CLASS
Generic attributes :
45:
Saturation             : Saturated
Number of Carbon Atoms : less than 7

Element Count :
Node 45: Limited
    C,C1-6




L44     STRUCTURE UPLOADED

=> que L44 AND L42 NOT L43

L45  QUE L44 AND L42 NOT L43

=> d l45
L45 HAS NO ANSWERS
L42             SCR 1839
L43             SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L44             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L45             QUE  L44 AND L42 NOT L43


=> s l45 sss sam
SAMPLE SEARCH INITIATED 17:47:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  16584 TO ITERATE

  6.0% PROCESSED    1000 ITERATIONS                                2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       323969 TO   339391
PROJECTED ANSWERS:             318 TO     1008

L46           2 SEA SSS SAM L44 AND L42 NOT L43

=> => s l45 sss ful
FULL SEARCH INITIATED 17:48:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 326669 TO ITERATE
```

```
100.0% PROCESSED  326669 ITERATIONS                    1439 ANSWERS
SEARCH TIME: 00.00.06

L47        1439 SEA SSS FUL L44 AND L42 NOT L43

=> => s l47
L48         187 L47

=> s cough?
L49        5176 COUGH?

=> s orl?
L50        4568 ORL?

=> s opioid?
L51       38671 OPIOID?

=> s tussiv? or antitussiv?
            55 TUSSIV?
          3131 ANTITUSSIV?
L52        3159 TUSSIV? OR ANTITUSSIV?

=> s nocicept?
L53       10087 NOCICEPT?

=> s l49 or l50 or l51 or l52 or l53
L54       56671 L49 OR L50 OR L51 OR L52 OR L53

=> s l48 and l54
L55          31 L48 AND L54

=> d l55 1-31 bib,ab,hitstr
```

L55 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:162035 CAPLUS
DN 142:233377
TI Pharmaceutical composition and method using a combination of an **opioid** receptor antagonist and an α2δ ligand for the prevention and treatment of addiction in a mammal
IN Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy, Stanton Furst; McLean, Stafford
PA Pfizer Inc., USA
SO U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005043345	A1	20050224	US 2004-870821	20040617
WO 2005018670	A1	20050303	WO 2004-IB2602	20040809

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-497372P P 20030822
AB Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of alc. use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compns. are comprised of a therapeutically effective combination of an **opioid** receptor antagonist and an α2δ ligand and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.
IT **778582-19-7 778582-23-3 778582-27-7**
778582-32-4 778582-34-6 778582-60-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**opioid** receptor antagonist-α2δ ligand combination for prevention and treatment of addiction)
RN 778582-19-7 CAPLUS
CN Methanesulfonamide, N-[3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-23-3 CAPLUS

CN Benzamide, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-27-7 CAPLUS
CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-32-4 CAPLUS
CN Ethanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-34-6 CAPLUS
CN Benzamide, 3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-60-8 CAPLUS
CN Benzamide, 3-[3-[(1-hydroxy-3-phenylcyclobutyl)methyl]-8-methoxy-3-

azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



L55 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:160837 CAPLUS
DN 142:233372
TI Pharmaceutical composition using a combination of an **opioid** receptor antagonist and a CB-1 receptor antagonist for the prevention and treatment of addiction in a mammal
IN Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy, Stanton Furst; McLean, Stafford
PA Pfizer Inc, USA
SO U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005043327	A1	20050224	US 2004-870209	20040617
WO 2005018645	A1	20050303	WO 2004-IB2596	20040809

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-496803P P 20030821
AB Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of alc. use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compns. are comprised of a therapeutically effective combination of an **opioid** receptor antagonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.
IT **778582-19-7 778582-23-3 778582-27-7**
778582-32-4 778582-34-6 778582-60-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**opioid** receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)
RN 778582-19-7 CAPLUS
CN Methanesulfonamide, N-[3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-23-3 CAPLUS

CN Benzamide, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-27-7 CAPLUS
CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-32-4 CAPLUS
CN Ethanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-34-6 CAPLUS
CN Benzamide, 3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-60-8 CAPLUS
CN Benzamide, 3-[3-[(1-hydroxy-3-phenylcyclobutyl)methyl]-8-methoxy-3-

azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



L55 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:872783 CAPLUS
DN 141:366141
TI Preparation of 3-azabicyclo[3.2.1]octane derivatives for use in pharmaceutical compositions as **opioid** receptor modulators
IN Coe, Jotham Wadsworth; Mchardy, Stanton Furst; Bashore, Crystal Gayle
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004089908	A2	20041021	WO 2004-IB1189	20040402
WO 2004089908	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
NL 1025932	A1	20041018	NL 2004-1025932	20040413
US 2004259859	A1	20041223	US 2004-824037	20040414
PRAI US 2003-462629P	P	20030414		

OS MARPAT 141:366141
AB 3-Azabicyclo[3.2.1]octanes, such as I [R = H, OH, CN, NH2, CONH2, alkyl, alkynyl, alkylsuflonylamino, etc.; R3 = alkyl, arylalkyl, heteroarylalkyl, etc.; R8 = H, OH, OMe] and specifically II, were prepared for therapeutic use in the treatment of disease states, disorders and conditions mediated by **opioid** receptors, such as irritable bowel syndrome, drug addiction, depression, anxiety, schizophrenia and eating disorders.
IT **778582-19-7P 778582-20-0P 778582-21-1P**
778582-22-2P 778582-23-3P 778582-24-4P
778582-25-5P 778582-27-7P 778582-29-9P
778582-30-2P 778582-31-3P 778582-32-4P
778582-33-5P 778582-34-6P 778582-35-7P
778582-36-8P 778582-37-9P 778582-38-0P
778582-39-1P 778582-40-4P 778582-41-5P
778582-42-6P 778582-43-7P 778582-44-8P
778582-45-9P 778582-46-0P 778582-47-1P
778582-48-2P 778582-49-3P 778582-50-6P
778582-51-7P 778582-52-8P 778582-53-9P
778582-54-0P 778582-55-1P 778582-56-2P
778582-57-3P 778582-58-4P 778582-59-5P
778582-60-8P 778582-61-9P 778582-62-0P
778582-63-1P 778582-64-2P 778582-65-3P
778582-66-4P 778582-67-5P 778582-68-6P
778582-69-7P 778582-70-0P 778582-71-1P
778582-72-2P 778582-73-3P 778582-74-4P
778582-75-5P 778582-76-6P 778582-77-7P
778582-78-8P 778582-79-9P 778582-80-2P
778582-81-3P 778582-82-4P 778582-83-5P

778582-84-6P 778582-85-7P 778582-86-8P
778582-87-9P 778582-88-0P 778582-89-1P
778582-90-4P 778582-91-5P 778582-92-6P
778582-93-7P 778582-94-8P 778582-95-9P
778582-96-0P 778582-97-1P 778582-98-2P
778582-99-3P 778583-01-0P 778583-05-4P
778583-07-6P 778583-09-8P 778583-11-2P
778583-12-3P 778583-14-5P 778583-17-8P
778583-18-9P 778583-19-0P 778583-20-3P
778583-21-4P 778583-22-5P 778583-23-6P
778583-24-7P 778583-25-8P 778583-26-9P
778583-27-0P 778583-28-1P 778583-29-2P
778583-30-5P 778583-31-6P 778583-32-7P
778583-35-0P 778583-36-1P 778583-38-3P
778583-39-4P 778583-40-7P 778583-42-9P
778583-43-0P 778583-44-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-azabicyclo[3.2.1]octane derivs. for use in pharmaceutical compns. as **opioid** receptor modulators)

RN 778582-19-7 CAPLUS
CN Methanesulfonamide, N-[3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-20-0 CAPLUS
CN Phenol, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-21-1 CAPLUS
CN Ethanesulfonamide, N-[3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-22-2 CAPLUS
CN Methanesulfonamide, N-[3-[8-hydroxy-3-[3-(1-hydroxycyclohexyl)propyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-23-3 CAPLUS
CN Benzamide, 3-[3-[3-(1-hydroxycyclohexyl)propyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-24-4 CAPLUS
CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-[3-(1-hydroxycyclohexyl)propyl]-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 778582-25-5 CAPLUS
CN Benzamide, 3-[3-(cyclopropylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-27-7 CAPLUS
CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-29-9 CAPLUS
CN 1H-Inden-2-ol, 2,3-dihydro-2-[[8-(3-hydroxyphenyl)-8-methoxy-3-azabicyclo[3.2.1]oct-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 778582-30-2 CAPLUS
CN Ethanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-31-3 CAPLUS
CN Methanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-32-4 CAPLUS
CN Ethanesulfonamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-33-5 CAPLUS
CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 778582-34-6 CAPLUS
CN Benzamide, 3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-35-7 CAPLUS
CN Ethanone, 1-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 778582-36-8 CAPLUS
CN Benzamide, 3-(3-ethyl-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)



RN 778582-37-9 CAPLUS
CN Benzamide, 3-[8-methoxy-3-(3-methylbutyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-38-0 CAPLUS
CN Benzamide, 3-(8-methoxy-3-pentyl-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)



RN 778582-39-1 CAPLUS
CN Benzamide, 3-[8-methoxy-3-(1H-pyrrol-2-ylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-40-4 CAPLUS
CN Benzamide, 3-(3-hexyl-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)



RN 778582-41-5 CAPLUS
CN Benzamide, 3-[3-(2-ethylbutyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-42-6 CAPLUS
CN Benzamide, 3-[8-methoxy-3-[(1-methyl-1H-pyrrol-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-43-7 CAPLUS
CN Benzamide, 3-[8-methoxy-3-(3-thienylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-44-8 CAPLUS
CN Benzamide, 3-[8-methoxy-3-(2-thiazolylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-45-9 CAPLUS
CN Benzamide, 3-(8-methoxy-3-octyl-3-azabicyclo[3.2.1]oct-8-yl)- (9CI) (CA INDEX NAME)



RN 778582-46-0 CAPLUS
CN Benzamide, 3-[8-methoxy-3-(3-phenyl-2-propynyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-47-1 CAPLUS
CN Benzamide, 3-[8-methoxy-3-(3-phenylpropyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-48-2 CAPLUS
CN Benzamide, 3-[3-(1H-indol-3-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-49-3 CAPLUS
CN Benzamide, 3-[3-(2-benzofuranylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-50-6 CAPLUS
CN Benzamide, 3-[8-methoxy-3-(2-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-51-7 CAPLUS
CN Benzamide, 3-[8-methoxy-3-(3-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-52-8 CAPLUS
CN Benzamide, 3-[3-[(4-chloro-2-fluorophenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-53-9 CAPLUS
CN Benzamide, 3-[8-methoxy-3-[(1-methyl-1H-indol-3-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-54-0 CAPLUS
CN Benzamide, 3-[8-methoxy-3-[2-(2-phenylethoxy)ethyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-55-1 CAPLUS
CN Ethanesulfonamide, N-[3-(8-hydroxy-3-pentyl-3-azabicyclo[3.2.1]oct-8-

yl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-56-2 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-methylbutyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-57-3 CAPLUS
CN Benzamide, 3-[3-[(4-hydroxy-1-naphthalenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-58-4 CAPLUS
CN Benzamide, 3-[8-methoxy-3-[[4-(1-pyrrolidinyl)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-59-5 CAPLUS
CN Benzamide, 3-[8-methoxy-3-[(3-methylbenzo[b]thien-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-60-8 CAPLUS
CN Benzamide, 3-[3-[(1-hydroxy-3-phenylcyclobutyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-61-9 CAPLUS
CN Ethanesulfonamide, N-[3-(3-hexyl-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-62-0 CAPLUS
CN Benzamide, 3-[3-([1,1'-biphenyl]-4-ylmethyl)-8-methoxy-3-

azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-63-1 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-pyridinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-64-2 CAPLUS
CN Benzamide, 3-[8-methoxy-3-[[3-(trifluoromethoxy)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-65-3 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-thienylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-66-4 CAPLUS
CN Ethanesulfonamide, N-[3-[3-(cyclohexylmethyl)-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-67-5 CAPLUS
CN Benzamide, 3-[3-(9H-fluoren-2-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-68-6 CAPLUS
CN Benzamide, 3-[8-methoxy-3-[(3-phenoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-69-7 CAPLUS
CN Benzamide, 3-[3-[[4-(dimethylamino)-1-naphthalenyl]methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-70-0 CAPLUS

CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(2-phenylethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-71-1 CAPLUS
CN Ethanesulfonamide, N-[3-(8-hydroxy-3-octyl-3-azabicyclo[3.2.1]oct-8-yl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-72-2 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-phenyl-2-propynyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-73-3 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-phenylpropyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-74-4 CAPLUS
CN Ethanesulfonamide, N-[3-[3-[(4-chlorophenyl)methyl]-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-75-5 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(1H-indol-3-ylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-76-6 CAPLUS
CN Ethanesulfonamide, N-[3-[3-(2-benzofuranylmethyl)-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-77-7 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(2-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-78-8 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(1-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-79-9 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(4-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-80-2 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(3-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-81-3 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(1-methyl-1H-indol-3-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-82-4 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[2-(2-phenylethoxy)ethyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-83-5 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(4-hydroxy-1-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-84-6 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[[4-(1-pyrrolidinyl)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-85-7 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(3-methylbenzo[b]thien-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-86-8 CAPLUS
CN Ethanesulfonamide, N-[3-[3-([1,1'-biphenyl]-4-ylmethyl)-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-87-9 CAPLUS
CN Ethanesulfonamide, N-[3-[3-(9H-fluoren-2-ylmethyl)-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-88-0 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(3-phenoxyphenyl)methyl]-3-

azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-89-1 CAPLUS
CN Ethanesulfonamide, N-[3-[3-[[4-(dimethylamino)-1-naphthalenyl]methyl]-8-hydroxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-90-4 CAPLUS
CN Methanesulfonamide, N-[3-[3-(cyclopropylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-91-5 CAPLUS
CN Benzamide, 3-[8-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-92-6 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-(2-methylpropyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-93-7 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-(3-methylbutyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-94-8 CAPLUS
CN Methanesulfonamide, N-[3-(8-methoxy-3-pentyl-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 778582-95-9 CAPLUS
CN Methanesulfonamide, N-[3-[3-(2-ethylbutyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-96-0 CAPLUS
CN Methanesulfonamide, N-[3-(3-hexyl-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 778582-97-1 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-(3-pyridinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-98-2 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-(2-thiazolylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-99-3 CAPLUS
CN Methanesulfonamide, N-[3-(3-heptyl-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 778583-01-0 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-05-4 CAPLUS
CN Methanesulfonamide, N-[3-[3-[(4-fluorophenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-07-6 CAPLUS
CN Methanesulfonamide, N-[3-[3-(2-ethylhexyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-09-8 CAPLUS
CN Methanesulfonamide, N-[3-(8-methoxy-3-octyl-3-azabicyclo[3.2.1]oct-8-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 778583-11-2 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-12-3 CAPLUS
CN Methanesulfonamide, N-[3-[3-[(4-chlorophenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-14-5 CAPLUS
CN Methanesulfonamide, N-[3-[3-(1H-indol-3-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-17-8 CAPLUS
CN Methanesulfonamide, N-[3-[3-(2-benzofuranylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-18-9 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-(1-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-19-0 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-(2-naphthalenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-20-3 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-(4-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-21-4 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-(3-quinolinylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-22-5 CAPLUS
CN Methanesulfonamide, N-[3-[3-[(4-chloro-2-fluorophenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-23-6 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-[(1-methyl-1H-indol-3-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-24-7 CAPLUS
CN Methanesulfonamide, N-[3-[3-[(4-hydroxy-1-naphthalenyl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-25-8 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-[[4-(1-pyrrolidinyl)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-26-9 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-[(3-methylbenzo[b]thien-2-yl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-27-0 CAPLUS
CN Methanesulfonamide, N-[3-[3-([1,1'-biphenyl]-4-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-28-1 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-[[3-(trifluoromethoxy)phenyl]methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-29-2 CAPLUS
CN Methanesulfonamide, N-[3-[3-(9H-fluoren-2-ylmethyl)-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-30-5 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-[(3-phenoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-31-6 CAPLUS
CN Methanesulfonamide, N-[3-[3-[[4-(dimethylamino)-1-naphthalenyl]methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-32-7 CAPLUS
CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-(3-cyclohexylpropyl)-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 778583-35-0 CAPLUS
CN Benzamide, 3-[8-hydroxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778583-36-1 CAPLUS
CN Benzamide, 3-[8-methoxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778583-38-3 CAPLUS
CN Methanesulfonamide, N-[3-[8-hydroxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-39-4 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-40-7 CAPLUS
CN Acetamide, N-[3-[3-[(2,3-dihydro-2-hydroxy-1H-inden-2-yl)methyl]-8-methoxy-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX

NAME)



RN 778583-42-9 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778583-43-0 CAPLUS
CN Ethanesulfonamide, 2-methoxy-N-[3-[8-methoxy-3-[(1,2,3,4-tetrahydro-2-hydroxy-2-naphthalenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778583-44-1 CAPLUS
CN 3-Azabicyclo[3.2.1]octan-8-ol, 3-(cyclopropylmethyl)-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



IT **778581-99-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 3-azabicyclo[3.2.1]octane derivs. for use in pharmaceutical

compns. as **opioid** receptor modulators)
RN 778581-99-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-aminophenyl)-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



IT **778581-81-0P 778581-83-2P 778581-93-4P**
778581-94-5P 778581-95-6P 778581-97-8P
778581-98-9P 778582-01-7P 778582-02-8P
778582-04-0P 778582-06-2P 778582-07-3P
778582-08-4P 778582-10-8P 778582-11-9P
778582-13-1P 778582-15-3P 778582-16-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-azabicyclo[3.2.1]octane derivs. for use in pharmaceutical compns. as **opioid** receptor modulators)
RN 778581-81-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-methoxyphenyl)-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 778581-83-2 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 8-chloro-8-(3-methoxyphenyl)-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 778581-93-4 CAPLUS
CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-bromophenyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 778581-94-5 CAPLUS
CN Boronic acid, [3-[8-hydroxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778581-95-6 CAPLUS
CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-hydroxyphenyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 778581-97-8 CAPLUS
CN 3-Azabicyclo[3.2.1]octan-8-ol, 8-(3-aminophenyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 778581-98-9 CAPLUS
CN Methanesulfonamide, N-[3-[8-hydroxy-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-01-7 CAPLUS
CN Benzonitrile, 3-[8-hydroxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-02-8 CAPLUS
CN Benzamide, 3-[8-hydroxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-04-0 CAPLUS
CN Ethanesulfonamide, N-[3-[8-hydroxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 778582-06-2 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 8-(3-bromophenyl)-8-methoxy-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 778582-07-3 CAPLUS
CN Boronic acid, [3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-08-4 CAPLUS
CN Phenol, 3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-10-8 CAPLUS
CN Benzenamine, 3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-11-9 CAPLUS
CN Methanesulfonamide, N-[3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-13-1 CAPLUS
CN Ethanesulfonamide, 2-methoxy-N-[3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 778582-15-3 CAPLUS
CN Benzonitrile, 3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



RN 778582-16-4 CAPLUS
CN Benzamide, 3-[8-methoxy-3-(phenylmethyl)-3-azabicyclo[3.2.1]oct-8-yl]- (9CI) (CA INDEX NAME)



L55 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:376570 CAPLUS
DN 138:368776
TI Preparation of azabicyclo[3.2.1]octanols and related compounds as superior agonists for **nociceptin** receptor **ORL**-1
IN Tulshian, Deen; Ho, Ginny D.; Ng, Fay W.
PA Schering Corporation, USA
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003039469	A2	20030515	WO 2002-US35539	20021106
	WO 2003039469	A3	20031016		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2465871	AA	20030515	CA 2002-2465871	20021106
	US 2003119847	A1	20030626	US 2002-288976	20021106
	US 6727254	B2	20040427		
	EP 1442036	A2	20040804	EP 2002-802860	20021106
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002013907	A	20040928	BR 2002-13907	20021106
	JP 2005508367	T2	20050331	JP 2003-541761	20021106
PRAI	US 2001-333284P	P	20011107		
	WO 2002-US35539	W	20021106		

OS MARPAT 138:368776
AB Azabicyclo[3.2.1]octanes (shown as I; variables defined below; e.g. 8-[bis(2-chlorophenyl)methyl]-3-(2-pyrimidinyl)-8-azabicyclo[3.2.1]octan-3-ol) or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compns. thereof, and the use of said compds. in the treatment of pain, anxiety, **cough**, asthma, depression and alc. abuse are disclosed. For I: R is R4-heteroaryl or 1,4,5,6-tetrahydropyrimidin-2-yl; R1 is H or C1-C6 alkyl; R2 and R3 = -CH3, -OCH3, fluoro, chloro, bromo and iodo; R4 = 1 to 4 H, halo, (C1-C6) alkyl, -CN, -CF3, -OCF3, -(CH2)nOR5, -(CH2)nNR5R6, -(CH2)nNHSO2R5, -(CH2)nNH(CH2)2NR5R6, -(CH2)nNHC(O)NR5R7, -(CH2)NH(CH2)2OR5 and 1-piperazinyl; n is 0-3; R5 and R6 = H and C1-C3-alkyl; and R7 is H, C1-C3-alkyl or amino(C1-C3)alkyl. Although the methods of preparation are not claimed, 20 example prepns. are included. Ki values for binding of I to **nociceptin** are reported for 9 examples, e.g. 1.3 nM for 8-[bis(2-chlorophenyl)methyl]-3-(5-bromo-2-pyridinyl)-8-azabicyclo[3.2.1]octan-3-ol. The agonist activity (EC50) of I are 20-200 nM. Example tablet and capsule formulations and methods for their manufacture are described.
IT **524019-25-8P**, 8-[Bis(2-chlorophenyl)methyl]-3-(2-pyrimidinyl)-8-azabicyclo[3.2.1]octan-3-ol **524019-34-9P**, 8-[Bis(2-chlorophenyl)methyl]-3-(1-methylpyrazol-5-yl)-8-azabicyclo[3.2.1]octan-3-ol **524019-43-0P**, 1,1-Dimethylethyl [2-[[[[[6-[8-[bis(2-

chlorophenyl)methyl]-3-hydroxy-8-azabicyclo[3.2.1]oct-3-yl]-2-pyridinyl]methyl]amino]carbonyl]amino]ethyl]carbamate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of azabicyclooctanols and related compds. as superior agonists for **nociceptin** receptor **ORL**-1)

RN 524019-25-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 524019-34-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(1-methyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 524019-43-0 CAPLUS
CN Carbamic acid, [2-[[[[[6-[8-[bis(2-chlorophenyl)methyl]-3-hydroxy-8-azabicyclo[3.2.1]oct-3-yl]-2-pyridinyl]methyl]amino]carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **524019-26-9P**, 8-[Bis(2-chlorophenyl)methyl]-3-(5-ethyl-2-pyrimidinyl)-8-azabicyclo[3.2.1]octan-3-ol **524019-28-1P**,

8-[Bis(2-chlorophenyl)methyl]-3-[4-(1-piperazinyl)-2-pyrimidinyl]-8-azabicyclo[3.2.1]octan-3-ol **524019-30-5P**, 8-[Bis(2-chlorophenyl)methyl]-3-(2-pyridinyl)-8-azabicyclo[3.2.1]octan-3-ol **524019-31-6P**, 8-[Bis(2-chlorophenyl)methyl]-3-(6-methoxy-2-pyridinyl)-8-azabicyclo[3.2.1]octan-3-ol **524019-32-7P**, 8-[Bis(2-chlorophenyl)methyl]-3-methoxy-3-(2-pyrimidinyl)-8-azabicyclo[3.2.1]octane **524019-33-8P**, 8-[Bis(2-chlorophenyl)methyl]-3-(1H-pyrazol-5-yl)-8-azabicyclo[3.2.1]octan-3-ol **524019-35-0P**, 8-[Bis(2-chlorophenyl)methyl]-3-(1-methyl-1H-indol-2-yl)-8-azabicyclo[3.2.1]octan-3-ol **524019-36-1P**, 8-[Bis(2-chlorophenyl)methyl]-3-(1-methyl-1H-imidazol-2-yl)-8-azabicyclo[3.2.1]octan-3-ol **524019-37-2P**, 8-[Bis(2-chlorophenyl)methyl]-3-(3-pyridazinyl)-8-azabicyclo[3.2.1]octan-3-ol **524019-38-3P**, 8-[Bis(2-chlorophenyl)methyl]-3-(2-pyrazinyl)-8-azabicyclo[3.2.1]octan-3-ol **524019-39-4P**, 8-[Bis(2-chlorophenyl)methyl]-3-(4-pyrimidinyl)-8-azabicyclo[3.2.1]octan-3-ol **524019-42-9P**, 8-[Bis(2-chlorophenyl)methyl]-3-(5-bromo-2-pyridinyl)-8-azabicyclo[3.2.1]octan-3-ol **524019-48-5P**, N-(2-Aminoethyl)-N'-[[6-[8-[Bis(2-chlorophenyl)methyl]-3-hydroxy-8-azabicyclo[3.2.1]oct-3-yl]-2-pyridinyl]methyl]urea hydrochloride **524019-49-6P**, 3-[3-(Aminomethyl)-2-pyridinyl]-8-[Bis(2-chlorophenyl)methyl]-8-azabicyclo[3.2.1]octan-3-ol **524019-54-3P**, 8-[Bis(2-chlorophenyl)methyl]-3-[4-(methylamino)-2-pyridinyl]-8-azabicyclo[3.2.1]octan-3-ol **524019-56-5P**, 3-[6-[(2-Aminoethyl)amino]-2-pyridinyl]-8-[bis(2-chlorophenyl)methyl]-8-azabicyclo[3.2.1]octan-3-ol **524019-59-8P**, 8-[Bis(2-chlorophenyl)methyl]-3-(1,4,5,6-tetrahydro-2-pyrimidinyl)-8-azabicyclo[3.2.1]octan-3-ol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of azabicyclooctanols and related compds. as superior agonists for **nociceptin** receptor **ORL**-1)

RN 524019-26-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(5-ethyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 524019-28-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-[4-(1-piperazinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 524019-30-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 524019-31-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(6-methoxy-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 524019-32-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-[bis(2-chlorophenyl)methyl]-3-methoxy-3-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 524019-33-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 524019-35-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(1-methyl-1H-indol-2-yl)- (9CI) (CA INDEX NAME)



RN 524019-36-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(1-methyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 524019-37-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(3-pyridazinyl)- (9CI) (CA INDEX NAME)



RN 524019-38-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-pyrazinyl- (9CI) (CA INDEX NAME)





RN 524019-39-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 524019-42-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(5-bromo-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 524019-48-5 CAPLUS
CN Urea, N-(2-aminoethyl)-N'-[[6-[8-[bis(2-chlorophenyl)methyl]-3-hydroxy-8-azabicyclo[3.2.1]oct-3-yl]-2-pyridinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 524019-49-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-[3-(aminomethyl)-2-pyridinyl]-8-[bis(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 524019-54-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-[4-(methylamino)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 524019-56-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-[6-[(2-aminoethyl)amino]-2-pyridinyl]-8-[bis(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 524019-59-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(1,4,5,6-tetrahydro-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



IT **524019-29-2P**, 8-[Bis(2-chlorophenyl)methyl]-3-(4-chloro-2-pyrimidinyl)-8-azabicyclo[3.2.1]octan-3-ol **524019-41-8P**, 8-[Bis(2-chlorophenyl)methyl]-3-(5-bromo-4-pyrimidinyl)-8-azabicyclo[3.2.1]octan-3-ol **524019-45-2P**, 8-[Bis(2-chlorophenyl)methyl]-3-[6-(hydroxymethyl)-2-pyridinyl]-8-azabicyclo[3.2.1]octan-3-ol **524019-47-4P**, 3-[6-(Aminomethyl)-2-pyridinyl]-8-[Bis(2-chlorophenyl)methyl]-8-azabicyclo[3.2.1]octan-3-ol **524019-52-1P**, 8-[Bis(2-chlorophenyl)methyl]-3-[3-(hydroxymethyl)-2-pyridinyl]-8-azabicyclo[3.2.1]octan-3-ol **524019-55-4P**, 1,1-Dimethylethyl [2-[8-[bis(2-chlorophenyl)methyl]-3-hydroxy-8-azabicyclo[3.2.1]oct-3-yl]-4-pyridinyl]carbamate **524019-57-6P**, 8-[Bis(2-chlorophenyl)methyl]-3-(6-bromo-2-pyridinyl)-8-azabicyclo[3.2.1]octan-3-ol **524019-58-7P**, 1,1-Dimethylethyl [2-[6-[8-[bis(2-chlorophenyl)methyl]-3-hydroxy-8-azabicyclo[3.2.1]oct-3-

yl]-2-pyridinyl]aminoethyl]carbamate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azabicyclooctanols and related compds. as superior agonists for **nociceptin** receptor **ORL**-1)

RN 524019-29-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(4-chloro-2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 524019-41-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(5-bromo-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 524019-45-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-[6-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 524019-47-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-[6-(aminomethyl)-2-pyridinyl]-8-[bis(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 524019-52-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-[3-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 524019-55-4 CAPLUS
CN Carbamic acid, [2-[8-[bis(2-chlorophenyl)methyl]-3-hydroxy-8-azabicyclo[3.2.1]oct-3-yl]-4-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 524019-57-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-(6-bromo-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 524019-58-7 CAPLUS
CN Carbamic acid, [2-[[6-[8-[bis(2-chlorophenyl)methyl]-3-hydroxy-8-azabicyclo[3.2.1]oct-3-yl]-2-pyridinyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L55 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:293443 CAPLUS
DN 136:319370
TI Use of defined substances that bind to the sigma receptor for combating sarcoma and carcinoma
IN Van Amsterdam, Christoph
PA Merck Patent Gmbh, Germany
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002030422	A1	20020418	WO 2001-EP11710	20011011
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10050236	A1	20020425	DE 2000-10050236	20001011
AU 2002010527	A5	20020422	AU 2002-10527	20011011
PRAI DE 2000-10050236	A	20001011		
WO 2001-EP11710	W	20011011		

AB The invention relates to the use of a compound, selected from 3-[4-(4-phenyl-1,2-3,6-tetrahydro-1-pyridyl)butyl]indole-5-ol, 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenyl-propyl)piperazine, 1-(4-hydroxyphenyl)-2-(4-benzyl-1-piperidinyl)propanol, 3-(4-((3S)-3-benzyl-1-piperidyl)butyl)indole-5-carbonitrile, 3-(4-((3R)-3-benzyl-1-piperidyl)butyl)indole-5-carbonitrile, 6-(4-(4-(5-fluoro-3-indolyl)butyl)-1-piperazinyl)-2H-1-benzopyrane-2-one, (5S)-(-)-5-[4-(4-aminobenzyl)-1-piperidylmethyl]-3-(4-ethylphenyl)oxazolidine-2-one, 6-3-[4-(2,4-difluorobenzyl)-1-piperidyl]-1-oxopropyl-2,3-dihydrobenzoxazole-2-one. 3-(4-(3-(4-Fluorophenyl-hydroxymethyl)piperido-1-yl)butyl)-5-indole-carbonitrile, 2-(4-[3-(5H-dibenz[b,f]azepine-5-yl)propyl]-1-piperazinyl)ethanol, 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine, (5S)-(-)-5-(4-benzyl-1-piperidylmethyl)-3-(4-chlorophenyl)oxazolidine-2-one, 6-3-[4-(4-fluorobenzyl)-1-piperidyl]-2-methylpropionyl-2,3-dihydrobenzoxazole-2-one, (1R,2S)-(+)-4-(3-(4-benzyl-piperidino-1-yl)-1-hydroxy-2-methyl-propyl)phenol, (E)-4-(3-(4-benzyl-piperidino-1-yl)-2-methyl-propenyl)phenol, 3-(4-(4-(2,1,3-benzothiadiazole-5-yl)-1-piperazinyl)butyl)indole-5-carbonitrile, 6-(3-(4-(4-fluorobenzyl)-1-piperidyl)-2-propenyl)-2,3-dihydrobenzoxazole-2-one, 3-(4-trifluoromethylphenoxymethyl)pyrrolidine, 6-3-[4-(4-fluorobenzyl)-1-piperidyl]-propionyl-3H-benzothiazole-2-one, 4-[3-(4-fluorobenzyl)piperidino-1-yl]propoxyphenol, [2-(4-methoxy-3-phenethyloxy-phenyl)ethyl]dipropyl-amine. (1S,5R)-3-(2-(2-adamantyl)ethyl)-1,8,8-trimethyl-3-azabicyclo[3.2.1]octane, 6-3-[4-(2,4-difluorobenzyl)piperidino-1-yl]propionyl-3H-benzothiazole-2-one, 1-1-[2-(4-fluoro-phenyl)ethyl]piperidino-4-ylindane-1-ol, 1-[2-(4-fluoro-phenyl)ethyl]-4-(naphthalino-2-sulfinyl)piperidine, 1-(indole-4-yl)-4-[4-(4-fluorophenyl)butyl]piperazine, 3-(4-(2-(2-phenyl-ethyl)-1-piperidyl)-1-butyl)indole, 2-[4-(4-(3-indolyl)butyl)-1-piperazinyl]benzonitrile, etc.,

or the corresponding acids, bases, or salts, which may be used as σ-receptor ligands for treating carcinoma or sarcoma.

IT **161785-97-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substances that bind to the sigma receptor for combating sarcoma and carcinoma)

RN 161785-97-3 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-, (1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:78241 CAPLUS
DN 134:131434
TI Preparation of substituted piperidines as **nociceptin** receptor **ORL**-1 agonists for use in treating **cough**
IN Tulshian, Deen; Ho, Ginny D.; Silverman, Lisa S.; Matasi, Julius J.; Mcleod, Robbie L.; Hey, John A.; Chapman, Richard W.; Bercovici, Ana; Cuss, Francis M.
PA Schering Corporation, USA
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007050	A1	20010201	WO 2000-US1853	20000126
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6262066	B1	20010717	US 1999-359771	19990726
	CA 2379398	AA	20010201	CA 2000-2379398	20000126
	EP 1200087	A1	20020502	EP 2000-904560	20000126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000012801	A	20020507	BR 2000-12801	20000126
	JP 2003505420	T2	20030212	JP 2001-511934	20000126
	US 2001011092	A1	20010802	US 2001-769824	20010125
	US 6455527	B2	20020924		
	ZA 2002000275	A	20030411	ZA 2002-275	20020111
	NO 2002000392	A	20020325	NO 2002-392	20020125
	US 2003073690	A1	20030417	US 2002-155277	20020523
	US 6716846	B2	20040406		
	US 2004067950	A1	20040408	US 2003-464580	20030617
	US 2004152707	A1	20040805	US 2004-761977	20040121
PRAI	US 1998-94240P	P	19980727		
	US 1999-359771	A	19990726		
	US 2000-491780	A1	20000126		
	WO 2000-US1853	W	20000126		
	US 2001-769824	A3	20010125		
	US 2002-155277	A3	20020523		

OS MARPAT 134:131434
AB The title compds. [I; X1 = (un)substituted alkyl, cycloalkyl, aryl, etc.; X2 = CHO, CN, (un)substituted NH2, etc.; or X1 = (un)substituted benzofused heterocyclyl and X2 = H; or X1 and X2 together form an optionally benzofused spiro heterocyclyl group; R1-R4 = H, alkyl; or (R1 and R4) or (R2 and R3) or (R1 and R3) or (R2 and R4) together can form an alkylene bridge; Z1 = (un)substituted alkyl, aryl, heteroaryl, etc.; Z2 = H, Z1; Z3 = H, alkyl; or Z1-Z3, together with the carbon to which they are attached, form bicyclic saturated or unsatd. rings] and their pharmaceutically acceptable salts, useful as **ORL**-1 receptor agonists for the treatment of **cough**, alone or in combination with one or more agents for the treatment of **cough**, allergy or asthma symptoms,

were prepared and formulated. Thus, reacting 4-hydroxy-4-phenylpiperidine with α-bromodiphenylmethane in the presence of K2CO3 in CH3CN afforded 90% II which showed Ki of 13 nM against **ORL**-1 receptor binding.

IT **322473-56-3P 322473-57-4P 322473-58-5P**
322473-59-6P 322473-60-9P 322473-61-0P
322473-62-1P 322473-63-2P 322473-64-3P
322473-65-4P 322473-66-5P 322473-67-6P
322473-68-7P 322473-69-8P 322473-70-1P
322473-71-2P 322473-72-3P 322473-73-4P
322473-74-5P 322473-75-6P 322473-76-7P
322473-77-8P 322473-78-9P 322473-79-0P
322473-80-3P 322473-81-4P 322473-94-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted piperidines as **nociceptin** receptor **ORL**-1 agonists for use in treating **cough**)

RN 322473-56-3 CAPLUS
CN 9-Azabicyclo[3.3.1]nonan-3-ol, 9-(diphenylmethyl)-3-phenyl-, hydrochloride, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 322473-57-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-(diphenylmethyl)-3-phenyl-, hydrochloride, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 322473-58-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-methylphenyl)methyl]-3-phenyl-, hydrochloride, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 322473-59-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-phenyl-, hydrochloride, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 322473-60-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-fluorophenyl)methyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-61-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[(2-chlorophenyl)phenylmethyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-62-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[(2-methylphenyl)phenylmethyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-63-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-[2-(aminomethyl)phenyl]-8-[bis(2-chlorophenyl)methyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-64-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[(2-fluorophenyl)phenylmethyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-65-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-[2-(aminomethyl)phenyl]-8-[bis(2-methylphenyl)methyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-66-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-phenyl-8-(1-phenylpentyl)-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-67-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-phenyl-8-(1-phenylhexyl)-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-68-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-[2-(aminomethyl)phenyl]-8-[bis(2-fluorophenyl)methyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-69-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[(2-bromophenyl)phenylmethyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-70-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-bromophenyl)methyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-71-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-[2-(aminomethyl)phenyl]-8-[bis(2-bromophenyl)methyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-72-3 CAPLUS
CN Benzoic acid, 2-[[(3-endo)-3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]oct-8-yl]phenylmethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-73-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis[2-(hydroxymethyl)phenyl]methyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-74-5 CAPLUS
CN Benzaldehyde, 2,2'-[[(3-endo)-3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]oct-8-yl]methylene]bis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-75-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-ethylphenyl)methyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-76-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-methoxyphenyl)methyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-77-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[1-(2-methylphenyl)pentyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-78-9 CAPLUS
CN Benzoic acid, 2-[[(3-endo)-3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]oct-8-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-79-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-phenyl-8-[(2,3,5,6-tetrafluoro-4-methoxyphenyl)methyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-80-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[(2,6-dimethoxyphenyl)methyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-81-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-94-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **322473-83-6 322473-89-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of substituted piperidines as **nociceptin** receptor **ORL**-1 agonists for use in treating **cough**)
RN 322473-83-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-(diphenylmethyl)-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 322473-89-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-methylphenyl)methyl]-3-phenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:98519 CAPLUS
DN 132:137290
TI Preparation of piperidine derivatives as high affinity ligands for **nociceptin** receptor **ORL**-1
IN Tulshian, Deen; Ho, Ginny D.; Silverman, Lisa S.; Matasi, Julius J.; McLeod, Robbie L.; Hey, John A.; Chapman, Richard W.; Bercovici, Ana; Cuss, Francis M.
PA Schering Corporation, USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English

Common Appl.

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006545	A1	20000210	WO 1999-US14165	19990726
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2338206	AA	20000210	CA 1999-2338206	19990726
	AU 9952056	A1	20000221	AU 1999-52056	19990726
	AU 768607	B2	20031218		
	BR 9912495	A	20010502	BR 1999-12495	19990726
	EP 1100781	A1	20010523	EP 1999-937174	19990726
	EP 1100781	B1	20040922		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	TR 200100241	T2	20010621	TR 2001-200100241	19990726
	JP 2002521472	T2	20020716	JP 2000-562351	19990726
	TW 502021	B	20020911	TW 1999-88112624	19990726
	EP 1258244	A1	20021120	EP 2002-18161	19990726
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY				
	NZ 509033	A	20031128	NZ 1999-509033	19990726
	RU 2237060	C2	20040927	RU 2001-105910	19990726
	AT 277013	E	20041015	AT 1999-937174	19990726
	ZA 2001000150	A	20020107	ZA 2001-150	20010105
	NO 2001000467	A	20010326	NO 2001-467	20010126
PRAI	US 1998-122878	A	19980727		
	EP 1999-937174	A3	19990726		
	WO 1999-US14165	W	19990726		

OS MARPAT 132:137290
AB Compds. of formula I [wherein: the dotted line represents an optional double bond; X1 = (un)substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl; X2 = CHO, CN, optionally substituted amino, alkyl, or aryl; or X1 =(un)substituted benzofused heterocyclyl and X2 = H; or X1 and X2 together form an optionally benzofused spiro heterocyclyl group; R1, R2, R3 and R4 = independently H and alkyl, or (R1 and R4) or (R2 and R3) or (R1 and R3) or (R2 and R4) together can form an alkylene bridge of 1 to 3 carbon atoms; Z1 = (un)substituted alkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, or CO2(alkyl or substituted amino) or CN; Z2 = H or Z1; Z3 = H or alkyl; or Z1, Z2 and Z3, together with the carbon to which

they are attached, form bicyclic saturated or unsatd. rings] or pharmaceutically acceptable salt or solvate thereof useful as **nociceptin** receptor inhibitors for the treatment of pain, anxiety, **cough**, asthma, depression, and alc. abuse are disclosed. Compound II showed the Ki value of 13 nM in an in vitro test for **ORL**-1 receptor binding assay. Formulations are given.

IT **256941-84-1P 256941-85-2P 256941-86-3P**
256941-87-4P 256941-98-7P 256941-99-8P
256942-00-4P 256942-01-5P 256942-02-6P
256942-03-7P 256942-04-8P 256942-05-9P
256942-06-0P 256942-07-1P 256942-08-2P
256942-09-3P 256942-10-6P 256942-13-9P
256942-14-0P 256942-15-1P 256942-16-2P
256942-17-3P 256942-18-4P 256942-19-5P
256942-20-8P 256942-21-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine derivs. as high affinity ligands for **nociceptin** receptor **ORL**-1)

RN 256941-84-1 CAPLUS

CN 9-Azabicyclo[3.3.1]nonan-3-ol, 9-(diphenylmethyl)-3-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 256941-85-2 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-(diphenylmethyl)-3-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 256941-86-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-methylphenyl)methyl]-3-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 256941-87-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-chlorophenyl)methyl]-3-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 256941-98-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-fluorophenyl)methyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 256941-99-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[(2-chlorophenyl)phenylmethyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 256942-00-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[(2-methylphenyl)phenylmethyl]-3-phenyl-(9CI) (CA INDEX NAME)



RN 256942-01-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-[2-(aminomethyl)phenyl]-8-[bis(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 256942-02-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[(2-fluorophenyl)phenylmethyl]-3-phenyl-(9CI) (CA INDEX NAME)



RN 256942-03-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-[2-(aminomethyl)phenyl]-8-[bis(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 256942-04-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-phenyl-8-(1-phenylpentyl)- (9CI) (CA INDEX NAME)



RN 256942-05-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-phenyl-8-(1-phenylhexyl)- (9CI) (CA INDEX NAME)



RN 256942-06-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-[2-(aminomethyl)phenyl]-8-[bis(2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 256942-07-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[(2-bromophenyl)phenylmethyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 256942-08-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-bromophenyl)methyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 256942-09-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-[2-(aminomethyl)phenyl]-8-[bis(2-bromophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 256942-10-6 CAPLUS
CN Benzoic acid, 2-[(3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]oct-8-yl)phenylmethyl]- (9CI) (CA INDEX NAME)



RN 256942-13-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis[2-(hydroxymethyl)phenyl]methyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 256942-14-0 CAPLUS
CN Benzaldehyde, 2,2'-[(3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]oct-8-yl)methylene]bis- (9CI) (CA INDEX NAME)



RN 256942-15-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-ethylphenyl)methyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 256942-16-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[bis(2-methoxyphenyl)methyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 256942-17-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[1-(2-methylphenyl)pentyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 256942-18-4 CAPLUS
CN Benzoic acid, 2-[(3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]oct-8-yl)methyl]- (9CI) (CA INDEX NAME)



RN 256942-19-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 3-phenyl-8-[(2,3,5,6-tetrafluoro-4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 256942-20-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[(2,6-dimethoxyphenyl)methyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 256942-21-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:98517 CAPLUS
DN 132:151695
TI Preparation of cyclic amine derivatives
IN Takadoi, Masanori; Tanioka, Asao; Ikeda, Makoto; Fukuda, Yasumichi; Kojima, Akihiko
PA Kyorin Pharmaceuticals Co., Ltd., Japan
SO PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000006544	A1	20000210	WO 1999-JP4109	19990730
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2000103782	A2	20000411	JP 1999-212807	19990727
AU 9949312	A1	20000221	AU 1999-49312	19990730
PRAI JP 1998-217547	A	19980731		
JP 1999-212807	A	19990727		
WO 1999-JP4109	W	19990730		

OS MARPAT 132:151695
AB Title compds. [I; R1 is hydrogen or C1-C6 alkyl; X is hydrogen, hydroxyl or C1-C6 alkoxy; Y is alkylene or alkenylalkylene; A is a five, six or seven-membered cyclic amine which contains one nitrogen atom and may be bridged at any positions; B is an optionally substituted homo or heterocycle; C is an optionally substituted homo or heterocycle except indole ring; and n is 1 or 2], drug compns. containing title compds, and pharmaceutical acceptable salts thereof are prepared and tested as tachykinin antagonists exhibited antagonism against substance P and neuro kinin A receptors. The title compound II was prepared
IT **257633-64-0P 257633-65-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic amines)
RN 257633-64-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-methoxy-8-(2-phenylethyl)-3-[(phenylsulfinyl)methyl]- (9CI) (CA INDEX NAME)



RN 257633-65-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-[2-(3-benzofuranyl)ethyl]-3-methoxy-3-

[(phenylsulfinyl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:634154 CAPLUS
DN 127:314404
TI An aromatic moiety is not essential for pharmacophore binding to sigma binding sites: synthesis of N-alkylazacycloheptane derivatives as potent sigma ligands
AU Yamashita, Akitake; Takahashi, Nobuyuki; Mochizuki, Daisuke; Tsujita, Ryuichi; Yamada, Shinji; Kawakubo, Hiromu; Suzuki, Yukio; Watanabe, Hideyuki
CS Inst. Life Science, Asahi Chemical Industry, Shizuoka, 410-23, Japan
SO Bioorganic & Medicinal Chemistry Letters (1997), 7(17), 2303-2306
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier
DT Journal
LA English
AB Novel 3-(ω-(cycloalkyl)-alkyl-1,8,8-trimethyl)-3-azabicyclo[3.2.1]octanes that had no aromatic rings were synthesized. Binding studies showed that these compds. were potent sigma ligands. Due to their simple structures without extra functional groups, they are suitable tools with which to identify pharmacophores capable of binding strongly to sigma binding sites.
IT **161786-00-1 161786-01-2 161786-03-4 161786-04-5 161786-05-6 161786-06-7 161786-07-8 161786-09-0 161902-56-3 195600-91-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthesis of N-alkylazacycloheptane derivs. as potent sigma ligands)
RN 161786-00-1 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-cyclopentylethyl)-1,8,8-trimethyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-01-2 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-cyclohexylethyl)-1,8,8-trimethyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-03-4 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-cycloheptylethyl)-1,8,8-trimethyl-, (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 161786-04-5 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-cyclooctylethyl)-1,8,8-trimethyl-, (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 161786-05-6 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(4-cyclohexylbutyl)-1,8,8-trimethyl-, (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-06-7 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(3-cyclohexylpropyl)-1,8,8-trimethyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-07-8 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(cyclohexylmethyl)-1,8,8-trimethyl-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-09-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(2-tricyclo[3.3.1.13,7]dec-2-ylethyl)-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161902-56-3 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-cyclohexylethyl)-1,8,8-trimethyl-, (1R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195600-91-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(cyclohexylmethyl)-1,8,8-trimethyl-, (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:574512 CAPLUS
DN 127:248269
TI Preparation of azepine derivatives as σ-receptors
IN Takahashi, Nobuyuki; Mochizuki, Daisuke
PA Asahi Kasei Kogyo K. K., Japan
SO U.S., 28 pp., Cont.-in-part of U.S. Ser. No. 389,385, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5658923	A	19970819	US 1995-413285	19950330
	JP 06184113	A2	19940705	JP 1993-223744	19930908
	JP 08109129	A2	19960430	JP 1995-202166	19950808
	JP 2831952	B2	19981202		
PRAI	JP 1992-250158	A	19920918		
	JP 1992-267702	A	19921006		
	JP 1994-47012	A	19940317		
	US 1995-389385	B2	19950216		
	JP 1993-223745		19930908		

OS MARPAT 127:248269
AB An azepine compds. I (R = (a) Q, R1 = H, lower alkyl, lower alkoxy, hydroxy, halo, optionally substituted Ph, and n = 0, 1; (b) C5-8 cycloalkyl which is optionally substituted by lower alkyl, (c) norbornyl, (d) bicyclo[3.3.1]nonyl, (e) naphthyl, (f) 1,3-benzoxolyl, (g) pyridyl, or (h) thienyl; m = 0-4, and C* is an asym. carbon), and their nontoxic salts were prepared for treating diseases related to σ-receptor such as schizophrenia. Thus, (1S)-1,8,-trimethyl-3-azabicyclo[3.2.1]octane hydrochloride was treated with 1-adamantylacetic acid followed by reduction to give (1S)-3-[2-(1-adamantyl)ethyl]-1,8,-trimethyl-3-azabicyclo[3.2.1]octane. The binding Ki for II with σ-receptor was 0.26 nM.
IT **161785-97-3P 161786-00-1P 161786-01-2P**
161786-05-6P 161786-06-7P 161786-07-8P
161786-09-0P 161786-13-6P 161786-14-7P
161786-15-8P 161786-23-8P 161786-24-9P
161786-25-0P 161786-28-3P 161786-29-4P
161786-30-7P 161786-31-8P 161786-32-9P
161786-33-0P 161786-34-1P 161902-53-0P
161902-54-1P 161902-55-2P 161902-56-3P
161902-59-6P 161902-60-9P 161902-61-0P
161902-62-1P 161902-63-2P 161902-64-3P
161902-66-5P 161902-67-6P 161902-68-7P
161902-76-7P 161902-77-8P 161902-78-9P
161902-79-0P 161902-80-3P 161902-82-5P
161902-83-6P 161902-84-7P 161902-85-8P
161902-86-9P 161902-87-0P 161902-88-1P
161902-89-2P 161902-90-5P 161902-91-6P
161967-90-4P 161967-91-5P 161967-95-9P
161967-96-0P 161967-97-1P 161967-98-2P
161967-99-3P 161968-00-9P 170719-72-9P
170719-73-0P 170719-74-1P 170719-75-2P
170719-78-5P 170719-80-9P 170719-81-0P
170719-82-1P 170719-83-2P 170719-84-3P
170719-85-4P 170719-86-5P 170719-87-6P
195600-82-9P 195600-91-0P 195600-93-2P

195600-94-3P 195601-00-4P 195601-11-7P
195601-12-8P 195601-15-1P 195601-16-2P
195601-17-3P 195601-18-4P 195726-99-9P
195727-00-5P 195727-01-6P 195727-02-7P
195727-03-8P 195727-04-9P 195727-05-0P
195727-06-1P 195727-07-2P 195727-08-3P
195727-09-4P 195727-10-7P 195727-11-8P
195727-12-9P 195727-13-0P 195727-14-1P
195727-15-2P 195727-16-3P 195727-75-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azepine derivs. as σ-receptors)

RN 161785-97-3 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-, (1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-00-1 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-cyclopentylethyl)-1,8,8-trimethyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-01-2 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-cyclohexylethyl)-1,8,8-trimethyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-05-6 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(4-cyclohexylbutyl)-1,8,8-trimethyl-, (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-06-7 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(3-cyclohexylpropyl)-1,8,8-trimethyl-, (1S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-07-8 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(cyclohexylmethyl)-1,8,8-trimethyl-, (1R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-09-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(2-tricyclo[3.3.1.13,7]dec-2-ylethyl)-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-13-6 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[(hexahydro-2,5-methanopentalen-3a(1H)-yl)methyl]-1,8,8-trimethyl-, [3a(1S)-(2α,3aβ,5α,6aβ)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-14-7 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-bicyclo[3.3.1]non-9-ylethyl)-1,8,8-trimethyl-, (1S)- (9CI) (CA INDEX NAME)





RN 161786-15-8 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-23-8 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(3-tricyclo[3.3.1.13,7]dec-2-ylpropyl)-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-24-9 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)ethyl]-1,8,8-trimethyl-, [3a(1S)-(2α,3aβ,5α,6aβ)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-25-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(tricyclo[3.3.1.13,7]dec-2-ylmethyl)-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-28-3 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(1-naphthalenyl)ethyl]-, hydrochloride, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 161786-29-4 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(2-naphthalenyl)ethyl]-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 161786-30-7 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(2-pyridinyl)ethyl]-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 161786-31-8 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(4-pyridinyl)ethyl]-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 161786-32-9 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(3-pyridinyl)ethyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-33-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(1,3-benzodioxol-5-yl)ethyl]-1,8,8-trimethyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161786-34-1 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(2-thienyl)ethyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161902-53-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-54-1 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-cyclopentylethyl)-1,8,8-trimethyl-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-55-2 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-cyclohexylethyl)-1,8,8-trimethyl-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-56-3 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-cyclohexylethyl)-1,8,8-trimethyl-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 161902-59-6 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(4-cyclohexylbutyl)-1,8,8-trimethyl-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-60-9 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(3-cyclohexylpropyl)-1,8,8-trimethyl-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-61-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(cyclohexylmethyl)-1,8,8-trimethyl-, hydrochloride, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-62-1 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 161902-63-2 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(2-tricyclo[3.3.1.13,7]dec-2-ylethyl)-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-64-3 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(2-tricyclo[3.3.1.13,7]dec-2-ylethyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 161902-66-5 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[(hexahydro-2,5-methanopentalen-3a(1H)-yl)methyl]-1,8,8-trimethyl-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-67-6 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-bicyclo[3.3.1]non-9-ylethyl)-1,8,8-trimethyl-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)





● HCl

RN 161902-68-7 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-76-7 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(3-tricyclo[3.3.1.13,7]dec-2-ylpropyl)-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-77-8 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(3-tricyclo[3.3.1.13,7]dec-2-ylpropyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 161902-78-9 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)ethyl]-1,8,8-trimethyl-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-79-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(tricyclo[3.3.1.13,7]dec-2-ylmethyl)-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-80-3 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(tricyclo[3.3.1.13,7]dec-2-ylmethyl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 161902-82-5 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(2-pyridinyl)ethyl]-, monohydrochloride, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 161902-83-6 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(4-pyridinyl)ethyl]-, monohydrochloride, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 161902-84-7 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(1-naphthalenyl)ethyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161902-85-8 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(2-naphthalenyl)ethyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161902-86-9 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(2-pyridinyl)ethyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161902-87-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(3-pyridinyl)ethyl]-, monohydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-88-1 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(4-pyridinyl)ethyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 161902-89-2 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(1,3-benzodioxol-5-yl)ethyl]-1,8,8-trimethyl-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-90-5 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(2-thienyl)ethyl]-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161902-91-6 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(1-naphthalenyl)ethyl]-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 161967-90-4 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-, hydrochloride, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 161967-91-5 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(2-tricyclo[3.3.1.13,7]dec-2-ylethyl)-, hydrochloride, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 161967-95-9 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(3-tricyclo[3.3.1.13,7]dec-2-ylpropyl)-, hydrochloride, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 161967-96-0 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-(tricyclo[3.3.1.13,7]dec-2-ylmethyl)-, hydrochloride, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 161967-97-1 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(1-naphthalenyl)ethyl]-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161967-98-2 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(2-naphthalenyl)ethyl]-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161967-99-3 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(2-pyridinyl)ethyl]-, monohydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 161968-00-9 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(4-pyridinyl)ethyl]-, monohydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 170719-72-9 CAPLUS

CN Tricyclo[3.3.1.13,7]decan-1-ol, 4-[2-(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)ethyl]-, [4(1S)-(1α,3α,4α,5.beta.,7α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170719-73-0 CAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-ol, 4-[2-(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)ethyl]-, [4(1S)-(1α,3α,4β,5.beta.,7α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170719-74-1 CAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-ol, 4-[2-(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)ethyl]-, [4(1R)-(1α,3α,4α,5.beta.,7α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170719-75-2 CAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-ol, 4-[2-(1,8,8-trimethyl-3-

azabicyclo[3.2.1]oct-3-yl)ethyl]-, [4(1R)-(1α,3α,4β,5.bet
a.,7α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170719-78-5 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(5-methoxytricyclo[3.3.1.13,7]dec-2-
yl)ethyl]-1,8,8-trimethyl-, [2(1R)-(1α,2β,3β,5β,7.bet
a.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170719-80-9 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(5-chlorotricyclo[3.3.1.13,7]dec-2-
yl)ethyl]-1,8,8-trimethyl-, [2(1S)-(1α,2β,3β,5β,7.bet
a.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170719-81-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(5-chlorotricyclo[3.3.1.13,7]dec-2-

yl)ethyl]-1,8,8-trimethyl-, [2(1S)-(1α,2α,3β,5β,7.be
ta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170719-82-1 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(5-chlorotricyclo[3.3.1.13,7]dec-2-
yl)ethyl]-1,8,8-trimethyl-, [2(1R)-(1α,2β,3β,5β,7.bet
a.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170719-83-2 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(5-chlorotricyclo[3.3.1.13,7]dec-2-
yl)ethyl]-1,8,8-trimethyl-, [2(1R)-(1α,2α,3β,5β,7.be
ta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170719-84-3 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(5-
phenyltricyclo[3.3.1.13,7]dec-2-yl)ethyl]-, [2(1S)-

(1α,2β,3β,5β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170719-85-4 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(5-phenyltricyclo[3.3.1.13,7]dec-2-yl)ethyl]-, [2(1S)-(1α,2α,3β,5β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170719-86-5 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(5-phenyltricyclo[3.3.1.13,7]dec-2-yl)ethyl]-, [2(1R)-(1α,2β,3β,5β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170719-87-6 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(5-phenyltricyclo[3.3.1.13,7]dec-2-yl)ethyl]-, [2(1R)-(1α,2α,3β,5β,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195600-82-9 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-bicyclo[2.2.1]hept-2-ylethyl)-1,8,8-trimethyl-, [1S,2(1S,5R),4R]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195600-91-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(cyclohexylmethyl)-1,8,8-trimethyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195600-93-2 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(4-methylcyclohexyl)ethyl]-, [1R-(1α,5α)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195600-94-3 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(3-methyltricyclo[3.3.1.13,7]dec-1-yl)ethyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 195601-00-4 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(3-methyltricyclo[3.3.1.13,7]dec-1-yl)ethyl]-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 195601-11-7 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-bicyclo[2.2.1]hept-2-ylethyl)-1,8,8-trimethyl-, hydrochloride, [1S,2(1S,5R),4R]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 195601-12-8 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-cyclohexylethyl)-1,8,8-trimethyl-, hydrochloride, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 195601-15-1 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(cyclohexylmethyl)-1,8,8-trimethyl-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 195601-16-2 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(4-methylcyclohexyl)ethyl]-

, hydrochloride, [1R-(1α,5α)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 195601-17-3 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(3-methyltricyclo[3.3.1.13,7]dec-1-yl)ethyl]-, hydrochloride, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 195601-18-4 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(3-methyltricyclo[3.3.1.13,7]dec-1-yl)ethyl]-, hydrochloride, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 195726-99-9 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(5-chlorotricyclo[3.3.1.13,7]dec-2-yl)ethyl]-1,8,8-trimethyl-, [2(1S,5R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195727-00-5 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(5-methoxytricyclo[3.3.1.13,7]dec-2-yl)ethyl]-1,8,8-trimethyl-, [2(1S,5R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195727-01-6 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(5-phenyltricyclo[3.3.1.13,7]dec-2-yl)ethyl]-, [2(1S,5R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195727-02-7 CAPLUS
CN Tricyclo[3.3.1.13,7]decan-2-ol, 4-[2-(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)ethyl]-, [4(1S,5R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195727-03-8 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(4-phenyltricyclo[3.3.1.13,7]dec-2-yl)ethyl]-, [2(1S,5R)]-[partial]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 195727-04-9 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(4-phenyltricyclo[3.3.1.13,7]dec-2-yl)ethyl]-, [2(1R,5S)]-[partial]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 195727-05-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(5-methoxytricyclo[3.3.1.13,7]dec-2-yl)ethyl]-1,8,8-trimethyl-, [2(1R,5S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195727-06-1 CAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-ol, 4-[2-(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)ethyl]-, [4(1R,5S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195727-07-2 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(5-chlorotricyclo[3.3.1.13,7]dec-2-yl)ethyl]-1,8,8-trimethyl-, [2(1R,5S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195727-08-3 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(5-phenyltricyclo[3.3.1.13,7]dec-2-yl)ethyl]-, [2(1R,5S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195727-09-4 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(5-chlorotricyclo[3.3.1.13,7]dec-2-yl)ethyl]-1,8,8-trimethyl-, hydrochloride, [2(1S,5R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 195727-10-7 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(4-phenyltricyclo[3.3.1.13,7]dec-2-yl)ethyl]-, hydrochloride, [2(1S,5R)]-[partial]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 195727-11-8 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 1,8,8-trimethyl-3-[2-(4-phenyltricyclo[3.3.1.13,7]dec-2-yl)ethyl]-, hydrochloride, [2(1R,5S)]-[partial]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 195727-12-9 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(5-methoxytricyclo[3.3.1.13,7]dec-2-yl)ethyl]-1,8,8-trimethyl-, hydrochloride, [2(1R,5S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 195727-13-0 CAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-ol, 4-[2-(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)ethyl]-, hydrochloride, [4(1R,5S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 195727-14-1 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(5-chlorotricyclo[3.3.1.13,7]dec-2-yl)ethyl]-1,8,8-trimethyl-, hydrochloride, [2(1R,5S)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 195727-15-2 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-(5-methoxytricyclo[3.3.1.13,7]dec-2-yl)ethyl]-1,8,8-trimethyl-, hydrochloride, [2(1S,5R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 195727-16-3 CAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-ol, 4-[2-(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)ethyl]-, hydrochloride, [4(1S,5R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 195727-75-4 CAPLUS
CN Tricyclo[3.3.1.13,7]decan-1-ol, 4-[2-(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)ethyl]-, [4(1S,5R)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L55 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1993:93788 CAPLUS
DN 118:93788
TI **Opioid** properties of some derivatives of pethidine based on tropane
AU Casy, A. F.; Dewar, G. H.; Pascoe, R. A.
CS Sch. Pharm. Pharmacol., Univ. Bath, Bath, BA2 7AY, UK
SO Journal of Pharmacy and Pharmacology (1992), 44(10), 787-90
CODEN: JPPMAB; ISSN: 0022-3573
DT Journal
LA English
AB The preparation of some tropane analogs of pethidine and its reversed ester, chiefly with preferred 3α-m-hydroxyphenyl chair conformations, is described. The former were secured from tropan-3-one in a sequence of reactions involving cyanide attack, hydrolysis, Grignard attack and then rearrangements. The reversed ester was obtained by treating tropan-3-one with lithium Ph, followed by acylation. Configurational and conformational assignments follow from NMR anal. The antinociceptive potencies of these compds. in mice are reported, and discussed in relation to non-phenolic congeners and the 4-arylpiperidine moiety of morphine.
IT **145879-81-8P 145899-57-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and analgesic activity of)
RN 145879-81-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-carboxylic acid, 3-(3-hydroxyphenyl)-8-propyl-, ethyl ester, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 145899-57-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-carboxylic acid, 3-(3-methoxyphenyl)-8-(2-phenylethyl)-, ethyl ester, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **145879-72-7P 145879-73-8P 145879-74-9P**
145879-75-0P 145879-76-1P 145879-77-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 145879-72-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-carboxylic acid, 8-(cyclopropylmethyl)-3-(3-methoxyphenyl)-, ethyl ester, hydrochloride, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 145879-73-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-carboxylic acid, 8-(cyclopropylmethyl)-3-(3-hydroxyphenyl)-, ethyl ester, hydrochloride, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 145879-74-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-carboxylic acid, 3-(3-methoxyphenyl)-8-propyl-, ethyl ester, hydrochloride, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 145879-75-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-carboxylic acid, 3-(3-hydroxyphenyl)-8-propyl-, ethyl ester, hydrochloride, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 145879-76-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-carboxylic acid, 3-(3-methoxyphenyl)-8-(2-phenylethyl)-, ethyl ester, hydrochloride, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 145879-77-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-carboxylic acid, 3-(3-hydroxyphenyl)-8-(2-phenylethyl)-, ethyl ester, hydrochloride, exo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L55 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1991:464561 CAPLUS
DN 115:64561
TI Characterization of 9 slowly dissociated **opioid** ligands azabicyclononanes compounds to μ, δ, and κ receptors
AU Fan, Liqun; Jin, Wenqiao; Chi, Zhiqiang
CS Shanghai Inst. Mater. Med., Chin. Acad. Sci., Shanghai, 200031, Peop. Rep. China
SO Zhongguo Yaoli Xuebao (1991), 12(3), 245-9
CODEN: CYLPDN; ISSN: 0253-9756
DT Journal
LA Chinese
AB In the receptor binding assay, the relative affinity ratios of P-7548 (I, R = O2CEt), P-7556 I (R = OBz), and P-7618 I (R = cyclopentylcarbonyloxy) were 56:16:1, 1:4:1, and 6:0.2:1 at μ, δ, and κ sites, resp. These compds. possessed a tight binding to μ receptor. After washed 4 times, they still inhibited the [3H]ohmefentanyl binding by 70-80%. In the guinea pig ileum, they showed potent and persistent agonist activities, 607, 303, and 181 times resp. that of normorphine. These effects were readily antagonized by naloxone and Mr2266. In the mouse vas deferens (MVD), they also possessed long-lasting agonist activities. The effect of P-7556 on MVD was not antagonized by naloxone and Mr2266, indicating that P-7556 acted on δ receptor in MVD. In the rabbit vas deferens, P-7548, P-7556, and P-7618 antagonized the effect of U-50488H. Thus, these azabicyclononanes are a series of **opioid** ligands with μ, δ agonist and κ antagonist activities.
IT **92836-37-8**, P-7521 **99451-04-4**, P-7548
135052-73-2, P 7617 **135052-74-3**, P 7616
135052-75-4, P 7528 **135052-76-5**, P 7618
135052-77-6, P 7556 **135052-78-7**, P 7602
135052-79-8, P 7608
RL: BIOL (Biological study)
(**opioid** receptor binding of, μ- and δ- and κ- affinity in)
RN 92836-37-8 CAPLUS
CN Phenol, 3-[(9-syn)-9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 99451-04-4 CAPLUS
CN Phenol, 3-[syn-9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]-, propanoate (ester) (9CI) (CA INDEX NAME)



RN 135052-73-2 CAPLUS
CN 2-Butenoic acid, 3-[9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]phenyl ester, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 135052-74-3 CAPLUS
CN 3-Furancarboxylic acid, 3-[9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]phenyl ester, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 135052-75-4 CAPLUS
CN Cyclopropanecarboxylic acid, 3-[9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]phenyl ester, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 135052-76-5 CAPLUS
CN Cyclopentanepropanoic acid, 3-[9-methoxy-3-(2-phenylethyl)-3-

azabicyclo[3.3.1]non-9-yl]phenyl ester, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 135052-77-6 CAPLUS
CN Phenol, 3-[9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]-, benzoate (ester), syn- (9CI) (CA INDEX NAME)



RN 135052-78-7 CAPLUS
CN 3-Azabicyclo[3.3.1]nonane-3-ethanol, 9-(3-hydroxyphenyl)-9-methoxy-α-phenyl-, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 135052-79-8 CAPLUS
CN Phenol, 3-[9-methoxy-3-(1-methyl-2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]-, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L55 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1990:151616 CAPLUS
DN 112:151616
TI A potent and long-lasting ligand, azabicyclononane (P-7521)
AU Chi, Zhiqiang; Jin, Wenqiao
CS Shanghai Inst. Mater. Med., Chin. Acad. Sci., Shanghai, 200031, Peop. Rep. China
SO Progress in Clinical and Biological Research (1990), 328(Int. Narc. Res. Conf. (INRC) '89), 1-4
CODEN: PCBRD2; ISSN: 0361-7742
DT Journal
LA English
AB Competition expts. between P-7521 (I) and subtype-specific ligands for the μ, δ, and κ receptors of the mouse brain showed that I had a high affinity for the μ receptor, an intermediate affinity for the δ receptor, and a low affinity for the κ receptor; its relative affinities for these 3 receptors were 66:8:1, resp. I had agonist activity mainly on μ receptors in the guinea pig ileum and the mouse vas deferens. In the rabbit vas deferens, which contains only κ receptors, I antagonized inhibition by the κ ligand U-50488H, with no agonist action. I is proposed as a powerful probe for the study of **opioid** ligand-receptor interactions and of receptor purification
IT **92836-37-8**, P 7521
RL: PROC (Process)
(binding of, to **opioid** receptor subtypes, specificity of)
RN 92836-37-8 CAPLUS
CN Phenol, 3-[(9-syn)-9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L55 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:587311 CAPLUS
DN 111:187311
TI Preparation of [3H]3-(β-phenethyl)-9β-methoxy-9α-(m-hydroxyphenyl)-3-azabicyclo[3,3,1]nonane and characterization of its binding to **opioid** receptors of rat brain membrane
AU Ge, Banglun; Zheng, Hongping; Xu, Yunping; Zhong, Gaoren; Gong, Jialing
CS Shanghai Inst. Mater. Med., Chin. Acad. Sci., Shanghai, 200031, Peop. Rep. China
SO Zhongguo Yaolixue Yu Dulixue Zazhi (1989), 3(3), 187-91
CODEN: ZYYZEW; ISSN: 1000-3002
DT Journal
LA English
AB The title compound, [3H]P-7521, was prepared by reaction of Br-substituted P-7521 with 3H. The radiochem. purity was >95%. A saturable, specific binding of [3H]P-7521 to **opioid** receptors of rat brain membrane was demonstrated. Scatchard anal. indicated the existence of 2 binding sites (KD1 = 0.030 nM, KD2 = 0.75 nM). NaCl (100 mM) showed no effect on the specific binding of [3H]P-7521 to rat brain membrane. Of the specifically bound drug, 50% dissociated in 20 min, while the binding of therest declined extremely slowly, with 35% retained on the membrane after 4 h. Eighty-seven percent of the specifically bound [3H]P-7521 was not removed by 4 extensive washings. [3H]P-7521 may serve as a useful tool for research on **opioid** receptors.
IT **92836-37-8**, P-7521
RL: PROC (Process)
(binding of, to **opioid** receptors)
RN 92836-37-8 CAPLUS
CN Phenol, 3-[(9-syn)-9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **123384-62-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tritiation of)
RN 123384-62-3 CAPLUS
CN Phenol, 3-[9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]-, monobromo deriv. (9CI) (CA INDEX NAME)



D1—Br

L55 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:417552 CAPLUS
DN 111:17552
TI P 7521 - a new irreversible **opioid** ligand
AU Jin, Wenqiao; Fan, Liqun; Chen, Xinjian; Chi, Zhiqiang
CS Shanghai Inst. Mater. Med., Chin. Acad. Sci., Shanghai, 200031, Peop. Rep. China
SO Zhongguo Yaoli Xuebao (1989), 10(3), 205-10
CODEN: CYLPDN; ISSN: 0253-9756
DT Journal
LA English
AB In the receptor binding assay, P 7521 (I) was a potent **opioid** ligand which acted mainly on μ-receptor. The relative affinity ratio at μ, δ and κ sites was 66:8:1. The inhibitory effects of I were 1868 and 6060 times more potent than morphine on the elec. evoked contractions in guinea pig ileum and mouse vas deferens, resp. and were readily antagonized by naloxone and Mr 2266. Apparently I acts on μ-receptor in guinea pig ileum and mouse vas deferens. In rabbit vas deferens, the compound had no agonist activity, but could antagonize the inhibitory effect of U-50488 H, a κ-agonist, showing the antagonistic characterization was on κ-receptor. The dissociation of I binding to **opioid** receptor were very difficult in μ-binding assay and bioassays.
IT **92836-37-8**, P 7521
RL: BIOL (Biological study)
(as irreversible **opioid** ligand)
RN 92836-37-8 CAPLUS
CN Phenol, 3-[(9-syn)-9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L55 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:108035 CAPLUS
DN 110:108035
TI P-8502 - a new μ-selective **opioid** receptor ligand
AU Ge, Banglun; Zhang, Hongping; Xu, Yongping; Zheng, Weijun
CS Shanghai Inst. Mater. Med., Chin. Acad. Sci., Shanghai, 200031, Peop. Rep. China
SO Zhongguo Yaoli Xuebao (1989), 10(1), 13-16
CODEN: CYLPDN; ISSN: 0253-9756
DT Journal
LA Chinese
AB The analgesic action of P-8502 and P-8511 (I; R1 = NH2 or fumarylamido, resp.) was compared in mice and rats by the hot-plate and tail-flick methods. The selective binding of the drugs to the **opioid** receptor was also studied in rat brain membrane P2 fractions. Results indicated that P-8502 is a selective μ- **opioid** receptor ligand, whereas P-8511 has no such selectivity.
IT **119431-46-8**, P 8502 **119446-70-7**, P 8511
RL: BIOL (Biological study)
(analgesia from, as μ- **opioid** receptor ligand, selectivity in)
RN 119431-46-8 CAPLUS
CN Benzenamine, 4-[2-[(9-syn)-9-methoxy-9-(3-methoxyphenyl)-3-azabicyclo[3.3.1]non-3-yl]ethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 119446-70-7 CAPLUS
CN 2-Butenoic acid, 4-[[4-[2-[(9-syn)-9-methoxy-9-(3-methoxyphenyl)-3-azabicyclo[3.3.1]non-3-yl]ethyl]phenyl]amino]-4-oxo-, methyl ester, (2E)- (9CI) (CA INDEX NAME)



L55 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:18422 CAPLUS
DN 110:18422
TI Effects of the long-acting analgesic 3-(β-phenylethyl)-9β-methoxy-9α-(m-hydroxyphenyl)-3-azabicyclo[3,3,1]nonane (P-7521) on opiate receptor binding in vitro
AU Zhou, Dehe; Ge, Banglun; Xu, Xuejun; Chi, Zhiqiang
CS Shanghai Inst. Mater. Med., Chin. Acad. Sci., Shanghai, 200031, Peop. Rep. China
SO Zhongguo Yaoli Xuebao (1988), 9(6), 511-15
CODEN: CYLPDN; ISSN: 0253-9756
DT Journal
LA Chinese
AB Opiate receptor binding of the title compound and its derivs. (I; R1 = OMe, hydroxyphenyl, methylphenyl, etc.; R2 = OH or OMe) was compared with that of morphine and 14-hydroxydihydromorphazone in rat brain membrane prepns., as determined by inhibition of [3H]etorphine binding. The analgesic potencies were also compared in mice. The title compound bound tightly to the brain opiate receptors.
IT **92836-34-5 92836-36-7 92836-37-8**
99451-04-4
RL: BIOL (Biological study)
(analgesia from, brain opiate receptor binding in)
RN 92836-34-5 CAPLUS
CN 3-Azabicyclo[3.3.1]nonane, 9-methoxy-9-(3-methylphenyl)-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 92836-36-7 CAPLUS
CN 3-Azabicyclo[3.3.1]nonan-9-ol, 9-(3-hydroxyphenyl)-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 92836-37-8 CAPLUS
CN Phenol, 3-[(9-syn)-9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 99451-04-4 CAPLUS
CN Phenol, 3-[syn-9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]-, propanoate (ester) (9CI) (CA INDEX NAME)



L55 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1986:81878 CAPLUS
DN 104:81878
TI Effects of 5 derivatives of 3-azabicyclo[3,3,1]nonanes on isolated guinea pig ileum myenteric plexus-longitudinal muscle
AU Wang, Dayuan; Chi, Zhiqiang
CS Shanghai Inst. Mater. Med., Chin. Acad. Sci., Shanghai, 200031, Peop. Rep. China
SO Zhongguo Yaoli Xuebao (1985), 6(4), 236-8
CODEN: CYLPDN; ISSN: 0253-9756
DT Journal
LA Chinese
AB Five derivs. of 3-azabicyclo[3,3,1]nonanes (I, R1 = MeO or OH; R2 = MeO, 3-MeC6H4, 3-MeOC6H4, or 3-HOC6H4) all inhibited the contraction of guinea pig ileum myenteric plexus-longitudinal muscle (GPIML) induced by elec. stimulation. Except I (R1 = R2 = MeO) [52904-54-8], the inhibitory effects of all the compds. were more potent than that of morphine. The relatively specific μ receptor antagonist naloxone completely reversed their inhibitory effects. The concentration-response curves of these compds. were parallel to that of morphine. There were good correlations between inhibitory potencies on the GPIML and analgesic potencies (mouse hot-plate and writhing tests and rat tail-flick test), and binding affinities for the opiate receptors of mouse brain for these 5 compds. Apparently, the analgesic actions of these compds. are mainly related to μ receptors. The inhibitory potency of I (R1 = MeO; R2 = 3-HOC6H4) [**92836-37-8**] on the GPIML was 4134 times that of morphine, indicating that the compound had a high affinity for μ receptors in the GPIML.
IT **92836-34-5 92836-35-6 92836-36-7 92836-37-8**
RL: BIOL (Biological study)
(ileum response to, analgesia and μ-opiate receptors in relation to)
RN 92836-34-5 CAPLUS
CN 3-Azabicyclo[3.3.1]nonane, 9-methoxy-9-(3-methylphenyl)-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 92836-35-6 CAPLUS
CN 3-Azabicyclo[3.3.1]nonane, 9-methoxy-9-(3-methoxyphenyl)-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 92836-36-7 CAPLUS
CN 3-Azabicyclo[3.3.1]nonan-9-ol, 9-(3-hydroxyphenyl)-3-(2-phenylethyl)-(9CI) (CA INDEX NAME)



RN 92836-37-8 CAPLUS
CN Phenol, 3-[(9-syn)-9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L55 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1986:28684 CAPLUS
DN 104:28684
TI Preparation of tritium-labeled 3-(β-phenylethyl)-9β-methoxy-9α-(m-propionoxyphenyl)-3-azabicyclo[3.3.1]nonane and some characterizations of its binding with opiate receptor from rat brain
AU Zhou, Dehe; Li, Zhiyi; Ni, Chonghu; Wu, Yizhi; Chi, Zhiqiang; Tang, Guozhong; Qian, Baogen
CS Shanghai Inst. Mater. Med., Acad. Sinica, Shanghai, Peop. Rep. China
SO Kexue Tongbao (Foreign Language Edition) (1985), 30(3), 412-16
CODEN: KHTPBU; ISSN: 0454-0948
DT Journal
LA English
AB In order to study the action of P-7548 (I) [**99451-04-4**] and its analogs an opiate receptors, the title compound [[3H]P-7548 [99450-92-7]] was prepared by catalytic reduction of 3-(β-phenylethyl)-9β-methoxy-9α-(m-acryloylphenyl)-3-azabicyclo[3.3.1] nonane [**99450-93-8**] with tritium gas. Some characteristics of [3H]P-7548 binding to opiate receptors from rat brain membranes were studied and were related to the analgesic effects of I.
IT **99451-04-4**
RL: BIOL (Biological study)
(opiate receptors of brain binding by, analgesic activity in relation to)
RN 99451-04-4 CAPLUS
CN Phenol, 3-[syn-9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]-, propanoate (ester) (9CI) (CA INDEX NAME)



IT **99450-93-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of, with tritium)
RN 99450-93-8 CAPLUS
CN 2-Propenoic acid, 3-[9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]phenyl ester (9CI) (CA INDEX NAME)



L55 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1985:39762 CAPLUS
DN 102:39762
TI Relation between analgesic activity and opiate receptor binding affinity of 5 3-azabicyclo[3.3.1]nonane derivatives
AU Wang, Dayuan; Chi, Zhiqiang
CS Shanghai Inst. Mater. Med., Chin. Acad. Sci., Shanghai, 200031, Peop. Rep. China
SO Zhongguo Yaoli Xuebao (1984), 5(3), 158-63
CODEN: CYLPDN; ISSN: 0253-9756
DT Journal
LA Chinese
AB A good correlation was observed between analgesic activity of the 5 3-azabicyclo[3.3.1]nonanes I (R1 = OMe or OH; R2 = OMe, 3-MePh, 3-HOPh, or 3-MeOPh) tested in mice and rats, and inhibition of μ-receptor-specific ligand binding in mouse brain plasma membranes.
IT **92836-34-5 92836-35-6 92836-36-7**
92836-37-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(analgesic activity of, brain opiate receptor binding in relation to)
RN 92836-34-5 CAPLUS
CN 3-Azabicyclo[3.3.1]nonane, 9-methoxy-9-(3-methylphenyl)-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 92836-35-6 CAPLUS
CN 3-Azabicyclo[3.3.1]nonane, 9-methoxy-9-(3-methoxyphenyl)-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 92836-36-7 CAPLUS
CN 3-Azabicyclo[3.3.1]nonan-9-ol, 9-(3-hydroxyphenyl)-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 92836-37-8 CAPLUS
CN Phenol, 3-[(9-syn)-9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L55 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1975:97815 CAPLUS
DN 82:97815
TI Benzylamines
IN Keck, Johannes; Pieper, Helmut; Krueger, Gerd; Pueschmann, Sigfrid; Noll. Klaus R.
PA Thomae, Dr. Karl, G.m.b.H.
SO Ger. Offen., 89 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2318636	A1	19741031	DE 1973-2318636	19730413
	DE 2318636	B2	19760701		
	DE 2318636	C3	19770210		
	AT 7402023	A	19760115	AT 1974-2023	19740312
	AT 332375	B	19760927		
	ES 424432	A1	19760601	ES 1974-424432	19740320
	SU 517250	D	19760605	SU 1974-2012364	19740404
	US 3950393	A	19760413	US 1974-458099	19740405
	CH 592606	A	19771031	CH 1974-528577	19740409
	CH 609033	A	19790215	CH 1977-5284	19740409
	CH 609041	A	19790215	CH 1977-5286	19740409
	CH 609034	A	19790215	CH 1977-5287	19740409
	CH 609327	A	19790228	CH 1974-4931	19740409
	CH 609328	A	19790228	CH 1977-5283	19740409
	RO 70260	P	19800315	RO 1974-82360	19740409
	RO 69152	P	19810130	RO 1974-78362	19740409
	RO 69291	P	19830429	RO 1974-82361	19740409
	JP 50012030	A2	19750207	JP 1974-40859	19740410
	JP 56034582	B4	19810811		
	ZA 7402298	A	19751231	ZA 1974-2298	19740410
	HU 167971	B	19760128	HU 1974-TO959	19740410
	NO 138250	C	19780802	NO 1974-1350	19740410
	NL 7404965	A	19741015	NL 1974-4965	19740411
	DD 113748	C	19750620	DD 1974-177856	19740411
	GB 1469187	A	19770330	GB 1974-16254	19740411
	CA 1011748	A1	19770607	CA 1974-197507	19740411
	CS 188920	P	19790330	CS 1974-2629	19740411
	SE 411749	B	19800204	SE 1974-5020	19740411
	SE 411749	C	19800522		
	BE 813678	A1	19741014	BE 1974-143168	19740412
	FR 2225165	A1	19741108	FR 1974-13024	19740412
	PL 89811	P	19761231	PL 1974-170327	19740412
	PL 96888	P	19780131	PL 1974-181439	19740412
	PL 102867	P	19790430	PL 1974-181429	19740412
	ES 433891	A1	19761116	ES 1975-433891	19750117
	ES 433893	A1	19761116	ES 1975-433893	19750117
	ES 433894	A1	19761116	ES 1975-433894	19750117
	ES 433890	A1	19761201	ES 1975-433890	19750117
	ES 433892	A1	19761216	ES 1975-433892	19750117
	SU 521836	D	19760715	SU 1975-2101046	19750130
	SU 521837	D	19760715	SU 1975-2101059	19750130
	SU 522790	D	19760725	SU 1975-2101048	19750130
	SU 543341	D	19770115	SU 1975-2101061	19750130
	SU 645553	D	19790130	SU 1975-2101050	19750130

	AT 7505020	A	19751115	AT 1975-5020	19750701
	AT 331211	B	19760810		
	AT 7505023	A	19751115	AT 1975-5023	19750701
	AT 331212	B	19760810		
	AT 7505031	A	19760115	AT 1975-5031	19750701
	AT 332379	B	19760927		
	AT 7505021	A	19770315	AT 1975-5021	19750701
	AT 339885	B	19771110		
	AT 7505022	A	19770715	AT 1975-5022	19750701
	AT 7506429	A	19751115	AT 1975-6429	19750820
	AT 331218	B	19760810		
	US 4006246	A	19770201	US 1976-649481	19760115
	US 29628	E	19780509	US 1976-746954	19761202
PRAI	DE 1973-2318636	A	19730413		
	DE 1974-2402989	A	19740123		
	DE 1974-2405322	A	19740205		
	AT 1974-2023	A	19740312		
	ES 1974-424432	A3	19740320		
	US 1974-458099	A3	19740405		

AB Benzylamines RR1(R2NH)C6H2CH2NR3R4 (I; R and R1 = e.g., Cl, Br, F, CF3, CMe3, CN, CO2H; R2 = H, Ac, Bz; R3 and R4 = e.g., Me, Et, Me3C, cyclohexyl) were prepared by the reaction of substituted benzyl chlorides with amines, followed by bromination or chlorination of the aromatic ring or reactions of the side chains. Thus, 22 g 2,3-(AcNH)MeC6H3CH2Br reacted with 20 g Et2NH in 1.6 l. CCl4 to give 2,3-(AcNH)MeC6H3CH2NEt2. About 270 I were prepared, useful as **antitussives**, as tested on guinea pigs. LD50 data and pharmaceutical formulations were given.

IT **55463-28-0P 55463-31-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 55463-28-0 CAPLUS

CN Acetamide, N-[4-bromo-5-(1,1-dimethylethyl)-2-[(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 55463-31-5 CAPLUS

CN Benzenamine, 4-bromo-5-(1,1-dimethylethyl)-2-[(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L55 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1974:535978 CAPLUS
DN 81:135978
TI 3-Azabicyclo[3.3.1]nonanes
IN Ohki, Eiji; Oida, Sadao; Ohashi, Yoshihiko; Takagi, Hiromu
PA Sankyo Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 49061168	A2	19740613	JP 1972-102891	19721014
PRAI JP 1972-102891	A	19721014		

AB 4-Alkoxy-3,5-propanopiperidines I (R and R2 = lower alkyl; R1 = lower alkyl, aralkyl) are prepared by treating 4α (or 4β)-hydroxy analogs (I; R = H) with lower alkanols in the presence of acid. I are analgesic and **antitussive** agents (no data). Thus, 0.6 g 4α-hydroxy-4β-m-methoxyphenyl-1-phenethyl-3α,5α-propanopiperidine (II) was refluxed with 2 ml concentrated H2SO4 in 20 ml MeOH for 8 hr to give 0.4 g 4β-methoxy-4α-m-methoxyphenyl analog. Also prepared was I (R = R1 = R2 = Me). II was prepared by heating phenethylamine, cyclohexanone, 37% H2CO, and concentrated HCl in AcOH and treating the 1-phenethyl-3,5-propano-4-piperidone with m-MeOC6H4MgBr.

IT **42471-67-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(methanolysis of)
RN 42471-67-0 CAPLUS
CN 3-Azabicyclo[3.3.1]nonan-9-ol, 9-(3-methoxyphenyl)-3-(2-phenylethyl)-, anti- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **42471-71-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 42471-71-6 CAPLUS
CN 3-Azabicyclo[3.3.1]nonane, 9-methoxy-9-(3-methoxyphenyl)-3-(2-phenylethyl)-, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.


R
OMe
MeO
N
Ph
S

L55 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1974:499241 CAPLUS
DN 81:99241
TI 3,5-Propanopiperidine derivatives as potential analgesics
AU Ohki, Eiji; Oida, Sadao; Ohashi, Yoshihiko; Yoshida, Akira; Kamoshita, Katsuo; Takagi, Hiromu
CS Cent. Res. Lab., Sankyo Co., Ltd., Tokyo, Japan
SO Chemical & Pharmaceutical Bulletin (1974), 22(5), 1014-21
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
AB 4β-Methoxy-4α-phenyl-3α,5α-propanopiperidine derivs. were prepared and tested biologically. Introduction of m-hydroxy substituent into the phenyl group of these derivs. results in radical potentiation of analgesic and **antitussive** activities. Also, some N-carbamates of these derivs. exhibit appreciable anti-inflammatory effects with analgesic activity.
IT **42471-71-6P 52904-46-8P 92836-37-8P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation and pharmacol. of)
RN 42471-71-6 CAPLUS
CN 3-Azabicyclo[3.3.1]nonane, 9-methoxy-9-(3-methoxyphenyl)-3-(2-phenylethyl)-, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 52904-46-8 CAPLUS
CN 3-Azabicyclo[3.3.1]nonane, 9-methoxy-9-phenyl-3-(2-phenylethyl)-, anti- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 92836-37-8 CAPLUS
CN Phenol, 3-[(9-syn)-9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **33368-54-6P 42408-10-6P 42471-67-0P 52904-57-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33368-54-6 CAPLUS
CN 3-Azabicyclo[3.3.1]nonan-9-ol, 9-phenyl-3-(2-phenylethyl)-, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 42408-10-6 CAPLUS
CN 3-Azabicyclo[3.3.1]nonan-9-ol, 9-(3-methoxyphenyl)-3-(2-phenylethyl)-, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 42471-67-0 CAPLUS
CN 3-Azabicyclo[3.3.1]nonan-9-ol, 9-(3-methoxyphenyl)-3-(2-phenylethyl)-, anti- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 52904-57-1 CAPLUS
CN 3-Azabicyclo[3.3.1]nonan-9-ol, 9-phenyl-3-(2-phenylethyl)-, anti- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L55 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1973:453184 CAPLUS
DN 79:53184
TI Analgesic and **antitussive** 3α,5α-propano piperidines
IN Iwai, Issei; Ohki, Eiji; Oida, Sadao; Takagi, Hiromu; Ohashi, Yoshihiko
PA Sankyo Co., Ltd.
SO Ger. Offen., 23 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2257131	A1	19730524	DE 1972-2257131	19721117
	JP 48056680	A2	19730809	JP 1971-92574	19711118
	US 3812134	A	19740521	US 1972-304810	19721108
	SE 393610	B	19770516	SE 1972-14732	19721114
	GB 1374328	A	19741120	GB 1972-52675	19721115
	NL 7215631	A	19730522	NL 1972-15631	19721117
	FR 2160593	A1	19730629	FR 1972-40887	19721117
	CH 581623	A	19761115	CH 1972-16828	19721117
	DK 134518	B	19761122	DK 1972-5743	19721117
PRAI	JP 1971-92574	A	19711118		

AB Five title compds. (I, R = Me, PhCH2CH2; R1 = H, OH, OMe) were prepared and (or) used as analgesics and **antitussives**. Thus, Grignard reaction of 3-BrC6H4OMe with 1-methyl-3α,5α-propano-4-piperidone in Et2O gave 4α-hydroxy-4β-(3-methoxyphenyl)-1-methyl-3α,5α-propanopiperidine (II) and its 4β-hydroxy-4α-(3-methoxyphenyl) isomer (III). A mixture of II and III was refluxed in MeOH in the presence of H2SO4 8 hr to give I (R = Me, R1 = OMe). The LD50 was <200 mg I (R = PhCH2CH2, R1 = OMe)/kg s.c. in mice.

IT **42408-10-6P 42471-65-8P 42471-67-0P**
42471-71-6P 92836-37-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 42408-10-6 CAPLUS
CN 3-Azabicyclo[3.3.1]nonan-9-ol, 9-(3-methoxyphenyl)-3-(2-phenylethyl)-, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 42471-65-8 CAPLUS
CN 3-Azabicyclo[3.3.1]nonan-9-ol, 9-(3-hydroxyphenyl)-3-(2-phenylethyl)-, anti- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 42471-67-0 CAPLUS
CN 3-Azabicyclo[3.3.1]nonan-9-ol, 9-(3-methoxyphenyl)-3-(2-phenylethyl)-, anti- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 42471-71-6 CAPLUS
CN 3-Azabicyclo[3.3.1]nonane, 9-methoxy-9-(3-methoxyphenyl)-3-(2-phenylethyl)-, syn- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 92836-37-8 CAPLUS
CN Phenol, 3-[(9-syn)-9-methoxy-3-(2-phenylethyl)-3-azabicyclo[3.3.1]non-9-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L55 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1973:72380 CAPLUS
DN 78:72380
TI Terpene compounds as drugs. XV. Basic ethoxyethylethers of guaiacol and eugenol as **antitussives**
AU Mantegani, Antonio; Donetti, Arturo; Bonardi, Graziano; Molino, Cecilia; Casadio, Silvano
CS Res. Lab., Ist. De Angeli, Milan, Italy
SO Chimica Therapeutica (1972), 7(6), 483-5
CODEN: CHTPBA; ISSN: 0009-4374
DT Journal
LA English
AB The cyclic amines I (R = H, CH2:CHCH2) and 14 amines II (R = H, CH2:CHCH2; R1 = prenyl, geranyl, trans-2,2,6-trimethylcyclohexyl, bornyl, menthyl; R2 = H, Me, prenyl, geranyl) were prepared, for example, by condensing 4,2-R(MeO)C6H3OCH2CH2OCH2CH2Cl with the appropriate amine. The compds. showed **antitussive** activity in rats.
IT **39704-90-0P 39704-91-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 39704-90-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-[2-(2-methoxyphenoxy)ethoxy]ethyl]-1,8,8-trimethyl- (9CI) (CA INDEX NAME)



RN 39704-91-1 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[2-[2-[2-methoxy-4-(2-propenyl)phenoxy]ethoxy]ethyl]-1,8,8-trimethyl- (9CI) (CA INDEX NAME)



L55 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1970:477292 CAPLUS
DN 73:77292
TI Physiologically active 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-ones
IN Schmidt, Guenther; Engelhorn, Robert; Leitold, Matyas
PA Thomae, Dr. Karl, G.m.b.H.
SO S. African, 41 pp.
CODEN: SFXXAB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 6905933		19700226		
	DE 1795183			DE	
	FR 2016009			FR	
	GB 1277132			GB	
	US 3660380		19720000	US	
	US 3743734		19730000	US	
PRAI	DE		19680820		

AB The title compds. (I) inhibit secretions and the formation of ulcers and also show **antitussive** and antiemetic activity, with low toxicity. I are prepared by treating a 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one with a haloacetyl halide and treating the product with a secondary amine. The following I were prepared (R1, R2, and Z given); H, H, 4-methyl-1-piperazinyl (Q); Me, H, Q; H, H, NBu2; H, H, 1-piperazinyl; Me, H, Me; H, H, 2-methylpiperidino. About 25 other examples are given.

IT **28781-51-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 28781-51-3 CAPLUS
CN 6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)acetyl]- (8CI) (CA INDEX NAME)



L55 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1969:77825 CAPLUS
DN 70:77825
TI Suppressing **coughs** and increasing secretions in warm-blooded animals with N-(amino-3,5-dihalobenzyl)camphidines
IN Keck, Johannes
PA Boehringer Ingelheim G.M.b.H.
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3408446	A	19681029	US 1967-650204	19670630
	FI 40631	B	19681231	FI 1962-2033	19621113
	SE 300820	B	19680513	SE 1962-12370	19621119
	SE 300990	B	19680520	SE 1964-11622	19621119
	SE 300991	B	19680520	SE 1964-11623	19621119
	FI 40803	B	19690228	FI 1968-1338	19680513
	FI 40804	B	19690228	FI 1968-1405	19680520
PRAI	DE 1961-T21147	A	19611120		

AB The title compds. (I and II) are prepared from camphidine (III) and diacylamino-3,5-dihalobenzyl halides. Thus, 61.3 g. 3,5,4-Br2(Ac2N)C6H2CH2Br was dissolved in 1.5 l. CCl4, mixed with 14.6 g. Et3N and 77.5 g. of a 46.7% solution of III in tetralone, and refluxed 1 hr. After removal of Et3N.HCl, the filtrate was evaporated to dryness and the residue dissolved in 350 ml. EtOH and 190 ml. concentrated HCl. The solution was refluxed 25 hrs. to give I (X = Br).HCl, m. 238-41° (decomposition) (EtOH-Et2O). Similarly prepared were the following I.HCl and II.HCl (compound, X and m.p. given): II, Cl, 217-19° (decomposition); I, Cl, 224-6°; II, Br, 109-11°. The effective dose of these compds. is 25-50 mg./kg.

IT **21782-04-7P 21782-05-8P 21782-06-9P 21782-07-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 21782-04-7 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(4-amino-2,5-dibromobenzyl)-1,8,8-trimethyl-, hydrochloride (8CI) (CA INDEX NAME)



●x HCl

RN 21782-05-8 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-amino-3,5-dichlorobenzyl)-1,8,8-trimethyl-, hydrochloride (8CI) (CA INDEX NAME)



●x HCl

RN 21782-06-9 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(4-amino-3,5-dichlorobenzyl)-1,8,8-trimethyl-, hydrochloride (8CI) (CA INDEX NAME)



●x HCl

RN 21782-07-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-(2-amino-3,5-dibromobenzyl)-1,8,8-trimethyl-, hydrochloride (8CI) (CA INDEX NAME)



● x HCl

L55 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1967:46427 CAPLUS
DN 66:46427
TI Oxadiazoles, thiadiazoles, and triazoles
PA Thomae, Dr. Karl, G.m.b.H.
SO Brit., 31 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1053085		19661230		
	DE 1470363			DE	
	FR 1466258			FR	
	FR 4840			FR	
	US 3419575		19680000	US	
PRAI	DE		19640326		

AB The title compds. (I), in which X may be O, S, or NH, may have **antitussive**, analgesic, antipyretic, or hypoglycemic properties, depending upon the natures of the substituents and of X. To 160 g. BrCN in 400 ml. MeOH at 0° was added 220 g. Me2NCH2CONHNH2.HCl (II) in 2 l. MeOH. After the reactants had dissolved, the mixture was refluxed 2-4 hrs., the MeOH distilled, the residue dissolved in 150 ml. H2O, the solution made alkaline with KOH and extracted with CHCl3, and the exts. dried to give 71.3% 2-amino-5-(dimethylaminomethyl)-1,3,4-oxadiazole (Ia), m. 134-6° (EtOH). Similar treatment of 50 g. (MeEtCH)2NCH2CONHNH2 with 28 g. BrCN gave 84% 2-amino-5-(di-sec-butylaminomethyl)-1,3,4-oxadiazole, m. 140-2° (Me2CO); and 18 g. MePhNCH2CONHNH2, treated with 10.6 g. BrCN, gave 74% 2-amino-5-(N-methylanilinomethyl)-1,3,4-oxadiazole, m. 216-18° (EtOH). Ia was also prepared in 48.5% yield from 5 g. Me2NCH2CONHNHCSNH2.HCl (III) (m. 216-17°; from II and KSCN) and 21 g. PbO in 200 cc. refluxing EtOH, and in 40% yield from 48 g. Me2NCH2CONHNHCONH2 (monohydrochloride m. 197-8°) and 200 cc. POCl3 at reflux one hr. A mixture of 14 g. 1-(N-cyclohexyl-N-methylglycyl)-4-(p-tolylsulfonyl)semicarbazide [prepared from N-cyclohexyl-N-methylglycyl hydrazide and TsNCS (Ts = p-MeC6H4SO2)] and 70 cc. POCl3 was heated one hr. on a water bath, cooled, and diluted with 500 cc. petr. ether, the precipitate washed with petr. ether and dissolved in dilute NaOH, and the filtered solution adjusted to pH 7 by 10% HCl to give 21% 2-(p-toluenesulfonamido)-5-(N-cyclohexyl-N-methylaminomethyl)-1,3,4-oxadiazole, m. 232-5° (dilute HOAc). The β-(N-methyl-N-cyclohexylamino)propionaldehyde hydrochloride from 19 g. β-(N-methyl-N-cyclohexylamino)propionaldehyd e diethyl acetal (b11 144-6°) and 105 cc. 6N HCl, 33 cc. H2O, 13 g. H2NCSNHNH2.HCl, and 14.4 g. NaOAc was heated on a water bath, then oxidized by 67.7 g. K3Fe(CN)6 in 225 cc. H2O 2-3 hrs., and the mixture made alkaline and extracted with CHCl3 to give 68% 2-amino-5-(N-methyl-N-cyclohexylaminomethyl)-1,3,4-thiadiazole, m. 162-3° (Me2CO). Treatment of 12.2 g. α-(N-methyl-N-cyclohexylamino)acetaldehyde 4-phenylthiosemicarbazone (IV) in 250 cc. CHCl3 with 6.4 g. Br in 50 cc. CHCl3, evaporation, addition of absolute EtOH, addition of solid Na2CO3, filtration, and distillation gave a residue of 12% 2-anilino-5-(N-methyl-N-cyclohexylaminomethyl)-1,3,4-thiadiazole (Ib), m. 206-8° (MeOH-H2O). Oxidation of 12.2 g. gave IV in 200 cc. EtOH by 10.8 g. FeCl3.6H2O under reflux 5 hrs. 22% Ib. Concentrated H2SO4 (25 g.) and 5 g. III

kept at 40-50° 30 min., poured onto 500 g. ice, and neutralized by Na2CO3 gave 25% 2-amino-5-(dimethylaminomethyl)-1,3,4-thiadiazole, m. 218-21° (Et2O); Ac derivative hydrochloride m. 238-40° (MeOH); Bz derivative hydrochloride decomposed 160-1° (EtOH). A mixture of 46.2 g. Et2NCH2CH2C(:NH)OEt.HCl (from Et2NCH2CH2CN, MeOH, and HCl in dioxane) and 18.2 g. H2NNHCSNH2 in 120 cc. absolute EtOH refluxed 2-3 hrs. gave 19.5% 2-amino-5-(β-diethylaminoethyl)-1,3,4-thiadiazole, m. 158-60° (EtOAc). A mixture of 3.7 g. 2-amino-5-diethylaminomethyl-1,3,4-thiadiazole and 3.36 g. NaHCO3 in 30 cc. H2O with 8.24 g. o-MeOC6H4SO2Cl in 20 cc. Me2CO, after 5 hrs. at 20-50°, was acidified with HCl, evaporated to dryness, extracted with hot EtOH, filtered, and cooled to give 65% 2-(o-methoxybenzenesulfonamido)-5-(diethylaminomethyl)-1,3,4-thiadiazole hydrochloride, decomposed 236-8°. In a min. amount H2O were dissolved 10 g. Me2NCH2CONHNHC(:NH)NH2.2HCl (m. 226-8°) and a stoichiometric amount Na2CO3, the solution evaporated to dryness, 100 cc. PhMe added, then distilled, the residue dissolved in absolute EtOH, and the solution filtered. Ethanolic HCl was added to the filtrate to give 65% 3-dimethylaminomethyl-5-amino-1,2,4-triazole dihydrochloride, m. 233-6°. Similar treatment of 10 g. (CH2:CHCH2)2NCH2CONHNHC(:NH)NH2.2HCl (m. 178-80°) and 3.75 g. NaOH gave 67% 3-diallylaminomethyl-5-amino,1,2,4-triazole dihydrochloride, m. 153-7°; and 7.5 g. Me2NCH2CH2CONHNHC(:NH)NH2.2HCl (m. 172-6°) and 3.3 g. NaOH gave 58% 3-dimethylaminoethyl-5-amino-1,2,4-triazole, m. 180-3° (4:1 EtOAc-EtOH). Addnl. I were prepared which are given in tabular form. The following novel intermediates were prepared by known methods as starting materials: Et2NCH2CH2CONHNHC(:NH)NH2.2HCl, m. 191-3°; QCH2CONHNHC(:NH)NH2.2HCl (Q = morpholino), m. 240-2°; QCH2CH2CONHNHC(:NH)NH2.2HCl, m. 238-9°; C6H11NMeCH2CONHNHCSNH2 (C6H11 = cyclohexyl), m. 206-8°; and C6H11NMeCH2CONHNHCSNHCH2CH:CH2, m. 118-20°. [TABLE OMITTED]

IT **14068-93-0P 14069-47-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 14068-93-0 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[(5-amino-1,3,4-thiadiazol-2-yl)methyl]-1,8,8-trimethyl- (8CI) (CA INDEX NAME)



RN 14069-47-7 CAPLUS
CN 3-Azabicyclo[3.2.1]octane, 3-[3-(5-amino-s-triazol-3-yl)propyl]-1,8,8-trimethyl- (8CI) (CA INDEX NAME)


Me
N
(CH2)3
H
N
NH2
N
N
Me
Me

L55 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1965:85701 CAPLUS
DN 62:85701
OREF 62:15314a-b
TI Pharmacological studies on guanethidine derivatives. III. Pharmacological actions of several guanethidine derivatives
AU Ozawa, Hikaru; Gomi, Yasuo; Otsuki, Isao
CS Tohoku Univ., Sendai, Japan
SO Yakugaku Zasshi (1965), 85(2), 112-19
CODEN: YKKZAJ; ISSN: 0031-6903
DT Journal
LA Japanese
AB cf. CA 61, 6237a. [2-(4-Methyl-4-aza-hexahydro-1H-azepin-1-yl)ethyl]guanidine sulfate (I) and [2-(4-(p-chlorophenyl)-hexahydro-1H-azepin-1-yl)ethyl]guanidine sulfate (II) showed a hypotensive action on rabbit, rat, and cat, but their activities were weaker than that of guanethidine (III). Unlike III, the pressor action of noradrenaline was not potentiated and that of tyramine was not inhibited by I and II. II and [2-(1,8,8-trimethyl-3-aza-bicyclo[3,2,1]oct-3-yl)ethyl] guanidine sulfate possessed a marked muscle relaxation on a preparation of Rana nigromaculata. Their activities were found to be almost the same as that of succinylcholine chloride. Analgesic, **antitussive** and antispasmodic activities were not as strong. An introduction of substituents in a 7-membered ring resulted in a decrease in hypotensive activity and an increase in toxicity.
IT **2847-69-0**, Guanidine, [2-(1,8,8-trimethyl-3-azabicyclo[3.2.1]-oct-3-yl)ethyl]-, sulfate
(effect on blood pressure, muscle-nerve transmission, etc.)
RN 2847-69-0 CAPLUS
CN Guanidine, [2-(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)ethyl]-, sulfate (7CI, 8CI) (CA INDEX NAME)

CM 1

CRN 13901-32-1
CMF C13 H26 N4



CM 2

CRN 7664-93-9
CMF H2 O4 S



L55 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1964:432184 CAPLUS
DN 61:32184
OREF 61:5564a-h
TI Preparation of new dihaloaminobenzylamines
PA Dr. Karl Thomae G.m.b.h.
SO 34 pp.
DT Patent
LA German

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 625022		19630520	BE	
	DE 1169939			DE	
	FR M2770			FR	
	GB 968254			GB	
PRAI	DE		19611120		

AB I, useful for pharmaceutical purposes, where X is Cl or Br, were prepared by (a) chlorination or bromination of aminobenzylamines, (b) amination of acylaminodihalobenzyl halide followed by hydrolysis, or (c) reduction of dihalonitrobenzylamines. Br (11.6 g.) in 50 cc. CHCl3 was added dropwise to 2-aminobenzyldiethylamine in 50 cc. CHCl3, the CHCl3 extracted with 100 cc. 2N NaOH and concentrated, and the residue dissolved in 50 cc. EtOH, and treated with HCl to give N-(2-amino- 3,5-dibromobenzyl)diethylamine-HCl (II), m. 214-14.5°. Br (39.5 g.) in 150 cc. AcOH was added dropwise to 12.6 g. N-(4- aminobenzyl)diethylamine in 150 cc. AcOH to give N-(4-amino-3,5-dibromobenzyl)diethylamine-HBr (III), m. 218° (decomposition) (EtOH). N- (2 - Amino - 3,5 - dibromobenzyl)diisobutylamine-HBr, m. 165-7°, was prepared similarly. 2-Diacetylamino-3,5- dibromobenzyl bromide (24.7 g.) was boiled 24 hrs. with 11.8 g. diallylamine in 300 cc. EtOH, the mixture distilled, the residue dissolved in 1 l. 3N HCl, refluxed 12 hrs., made alkaline, and extracted with CHCl3 to give N-(2-amino-3,5-dibromobenzyl)diallylamine- HCl, m. 109-13°. Prepared in similar manner were N-(4-amino- 3,5-dibromobenzyl)diallylamine-HCl, m. 191-5°, N-(2-Amino- 3,5-dibromobenzyl) - N - methylcyclohexylamine - HCl (IV.HCl), m. 232-5°, and N-(4-amino-3,5-dibromobenzyl) -N-methylbenzy lamine-HBr, m. 202-6°. Other IV salts were prepared (salt and m.p. given): p-MeC6H4SO3H, 218 -19°; HClO4, 132.5-4°; H3PO4, 137-8.5°; HBr, 227.5-8°; (CO2H)2, 182-3°; HCl, 240-2°; HNO3, 135-6°; H2SO4, 108-9°. Br (34 g.) in 500 cc. CHCl3 was added portionwise to 17 g. N-(2-aminobenzyl)pyrrolidine in 500 cc. CHCl3 at the b.p. to give N-(2-amino-3,5- dibromobenzyl)pyrrolidine-HCl, m. 219-20°. N-(2-Amino-3,5- dibromobenzyl)piperidine-HCl, m. 244-5°, was prepared in similar manner to II. I (2-amino) prepared by method a were (X, R, R1, salt, m.p. given): Br, Me, Me, HCl, 235-7°; Br, Pr, Pr, HCl, 153-6°; Br, iso-Pr, iso-Pr, HCl, 159-60°; Br, C5H11, C5H11, HCl, 111-13°; Br, isohexyl, isohexyl, HCl, 209-15° Br, Et, PhCH2, HBr, 179-82°; Br, PhCH2, PhCH2, HBr, 192-6°; Br, Me, Me, HCl, 252-6°; Br, Pr, Pr, HBr, 227°; Br, iso-Pr, iso-Pr, HCl, 141-4°; Br, Me, C6H11, HCl, 232-5° Br, (RR1 =) pentamethylene, HBr, 224-6°; Br, Et, PhCH2, HBr, 198-203°; Br, PhCH2, PhCH2, HCl, 233-5°. I (2-amino) prepared by method b were (X, R, R', salt, m.p. given): Br, C6H11, C6H11, HBr, 308-12°; Br, Et, Et, HCl, 123-30°; Br, (RR' =)tetramethylene, HCl, 200-5°; Br, Et, Ph, HCl, 211-15°. 3,5-Dichloro-2-acetamidotoluene (19 g.) was refluxed in 250 cc.Ac2O for 2 hrs. to give 3,5-dichloro-2-diacetylaminotoluene (V), m. 84-6° (EtOH). V (15.1 g.) was refluxed with 11.0 g. N-bromosuccinimide and 0.5 g. Bz2O in 250

cc. CCl4 to give 3,5,2-Cl2-(Ac2N)C6H2CH2Br (VI), m. 122-5°. VI (9.5 g.) was refluxed 18 hrs. with 5 g. piperidine and 250 cc. EtOH to produce N-(2- amino-3,5-dichlorobenzyl)piperidine-HCl, m. 234-5°. Prepared in similar manner were I (position of H2N, X, R, R', salt, and m.p. given): 4, Cl, Me, C6H11, -, - (free base m. 62-4°); 2, Cl, Me, C6H11, HCl, 224-5°; 2, Cl, iso-Bu, iso-Bu, HCl, 142-8°; 4, Cl, Et, Et, H2SO4, 132-4° 4, Cl, PhCH2, PhCH2, HCl, 237.5-238°; 2, Br, (RR'N =) camphidino, -, - (free base m. 109-11°); 4, Br, (RR'N =) camphidino, HCl, 238-41°. o-O2NC6H4CHO (1.51 g.) was refluxed 5 hrs. with 0.73 g. iso-BuNH2, distilled, the residue dissolved in 40 cc. AcOH and 1.64 g. AcoNa, 3.2 g. Br in 10 cc. AcOH added dropwise, and the mixture worked up with CCl4 to give 2.56 g. N-(2-amino-3,5-dibromobenzyl)isobutylamine (VII); VII.HCl X. 211-31°. Prepared in similar manner were I (position of H2N, X, R, R', salt, m.p. given): 4, Br, H, C6H11, HCl, 259-62°; 2, Br, H, C6H11, HCl, 247-8°; 4, Br, H, iso-Bu, HCl, 180-3°; 4, Br, cyclopentyl, cyclopentyl, HCl, 189-97°. N-(2-Nitro-3,5-dibromobenzyl)-N- methylcyclohexylammonium chloride was hydrogenated to produce N-(2-amino-3,5-dibromobenzyl-N-methylcyclohexylamine, m. 235-5.5° (EtOH). Prepared in same manner was I (2-amino): Br, H, Me, HBr, m. 244-7°. N-(2-Amino-3,5-dibromobenzyl) methylamine (4.4 g.) was heated 8 hrs. with 50 cc. EtOH and 1.9 g. PhCH2Cl, treated with 100 cc. 2N NaOH, extracted with CHCl3, dried over Na2SO4, concentrated. dissolved in

EtOH, treated with 2 cc. concentrated HBr and recrystd. from EtOH to give N-(2-amino-3,5-dibromobenzyl)-N-methylbenzylamine-HBr, m. 218.5-219°. I have low toxicities, abate secretions, calm **coughs**, inhibit monoamine oxidase, and are antipyretics. Pharmacol. tests are described.

IT **21782-04-7**, 3-Azabicyclo[3.2.1]octane, 3-(4-amino-3,5-dibromobenzyl)-1,8,8-tri-methyl-, hydrochloride **94804-17-8**, 3-Azabicyclo[3.2.1]octane, 3-(2-amino-3,5-dibromobenzyl)-1,8,8-trimethyl- (preparation of)

RN 21782-04-7 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 3-(4-amino-2,5-dibromobenzyl)-1,8,8-trimethyl-, hydrochloride (8CI) (CA INDEX NAME)



●x HCl

RN 94804-17-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 3-(2-amino-3,5-dibromobenzyl)-1,8,8-trimethyl- (7CI) (CA INDEX NAME)


Me
N
CH2
Br
Me
Me
H2N
Br

L55 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1963:403332 CAPLUS
DN 59:3332
OREF 59:547f-h,548a-d
TI Syntheses in the benzylamine series
AU Keck, Johannes
CS Dr. Karl Thomae G.m.b.H., Biberach, Germany
SO Ann. (1963), 662, 171-7
DT Journal
LA Unavailable
AB The preparation of a series of 2-amino- and 4-amino-3,5-dihalobenzylamines is described. Some of the new benzylamine derivs. surpass Vasicin in their physiol. action on the respiratory tract. o-O2NC6H4CH2Br (149 g.) and 80 g. 95% N-methylcyclohexylamine in 0.5 l. absolute EtOH refluxed 5 hrs., diluted with about 100 cc. H2O, concentrated, adjusted with 2N NaOH to pH 10, and extracted with CHCl3 yielded 149 g. N-(o-nitrobenzyl)-N-methylcyclohexylamine (I), b0.06 116-19°. I (300 g.) in 2 l. MeOH containing Raney Ni treated dropwise with stirring with 170 g. 80% N2H4.H2O in 0.5 l. MeOH and then with addnl. catalyst, and again 30 g. N2H4.H2O, refluxed 2 hrs., filtered, and distilled yielded 254 g. o-NH2 analog (II) of I, b0.08 109-11°. II (250 g.) in 2.5 l. AcOH treated dropwise with stirring with 420 g. Br in 0.5 l. AcOH, the supernatant decanted, the resinous residue shaken with 2 l. 5N NaOH and 2 l. CHCl3, and the residue from the CHCl3 phase dissolved in warm absolute EtOH and treated with dry HCl yielded 182 g. N-(3,5-dibromo-2-aminobenzyl)-N-methylcyclohexylammonium chloride (III), m. 237.5-38° (decomposition). 3,5,2-Cl2(AcNH)C6H2Me (19 g.) and 250 cc. Ac2O refluxed 2 hrs. and evaporated yielded 15.1 g. 3,5,2-Cl2(Ac2N)C6H2Me (IV), m. 84-6° (EtOH). IV (15.1 g.), 11.0 g. N-bromosuccinimide, and 0.5 g. Bz2O2 in 250 cc. CCl4 refluxed about 10 hrs., cooled, filtered, and evaporated gave 12.5 g. 3,5,2-Cl2(Ac2N)C6H2Br (V), m. 122-5° (EtOH). V (9.5 g.) and 5 g. piperidine in 250 cc. EtOH refluxed 18 hrs. and evaporated, the residue refluxed 18 hrs. with 1 l. 3N HCl, basified with 10N NaOH to pH 10, and extracted with CHCl3, and the oily residue from the extract dissolved in 50 cc. absolute EtOH and treated with dry HCl gave 2.3 g. N-(2-amino-3,5-dichlorobenzyl)piperidinium chloride, m. 234-5° (decomposition). Similarly was prepared the 3,5-Cl2 analog of III, m. 224-5°. 3,5,2-Br2(Ac2N)C6H2Me (2.0 g.) in 30 cc. CCl4 refluxed with 1.2 g. N-bromosuccinimide and 25 mg. Bz2O2 yielded 0.4 g. 3,5,2-Br2(Ac2N)C6H2CH2Br (VI), m. 116-17° (petr. ether). VI (3.3 g.) and 1.5 g. dry pyrrolidine in 70 cc. absolute EtOH refluxed 9 hrs., treated with 70 cc. 2N HCl, concentrated, washed with Et2O, basified with 10N NaOH, and extracted with Et2O gave 1.55 g. N-(3,5-dibromo-2-acetaminobenzyl)pyrrolidine (VII), m. 148-9° (petr. ether-EtOH). VII (1.55 g.) and 100 cc. 2N HCl refluxed 2 hrs., cooled, basified with 10N NaOH, and extracted with CHCl3, and the oily residue from the extract treated in a little absolute EtOH with concentrated HCl gave 0.5 g. N-(3,5-dibromo-2-aminobenzyl)pyrrolidinium chloride, m. 221.5-23°. By these methods were prepared the following 2,4,6-Br2(RCH2)C6H2NH2.HCl (R and m.p. given): Me2N, 230-2° (decomposition); Et2N, 217.5-19.5° (decomposition); Pr2N, 158-62°; (iso-Pr)2N, 179.5-82°; (iso-PrCH2CH2)2N, 151-6°; (CH2:CHCH2)2N, 123.5-5.5°; N-cyclohexyl-N-ethylamino, 206.5-209°; piperidino, 242.5-45°, 2-methylpiperidino, 212.5-16° (decomposition); 3-methylpiperidino, 224-7°; 4-methylpiperidino, 246.5-48° (decomposition); 2-ethylpiperidino, 223.5-5.5°; morpholino, 239-40.5° (decomposition); N-methyl-N-2-pyridylmethylamino, 198.5-201°; (PhCH2)2N,

221.5-23° (decomposition); 1,8,8-trimethyl-3-azabicyclo[3.2.1]-3-octyl, - (free base, m. 111-13°). Similarly were prepared the following 2,4,6-Br2(RCH2)C6H2NH2.HBr (R and m.p. given): Am2N, 123-4°; dicyclohexylamino, 307-9° (decomposition); Me(PhCH2)N, 218.5-19° (decomposition); Et(PhCH2)N, 187-9.5°. By the same methods were prepared the following 2,6,4-Br2(RCH2)C6H2NH2.HCl (R and m.p. given): Me2N, 250-3°; Et2N, 233-6°; Bu2N, 133.5-35°; iso-Bu2N, 152-5°; Am2N, 159-60.5°; (iso-Pr2CH2CH2)2N, 164.5-6.5°; (C6H13)2N, 80-4°; (CH2:CHCH2)2N, 190-7°; N-cyclohexyl-N-ethylamino, 210.5-12°; 2-methylpiperidino, 94-7°; 2-ethylpiperidino, 213-15°; (PhCH2)2N, 224.5-26°; N-methyl-N-2-pyridylmethylamino, 208-11° (decomposition); 1,8,8-trimethyl-8-azabicyclo[3.2.1]-3-octyl, 237-41°. Similarly were prepared the following 2,6,4-Br2(RCH2)C6H2NH2.HBr (R and m.p. given): piperidino, 233.5-4.5° (decomposition); Me(PhCH2)N, 195-9°; Et(PhCH2)N, 200-6°. In the same manner was obtained 2,6-dibromo-4-dibenzylaminoaniline-HCl, m. 237.5-38° (decomposition).

IT **21782-04-7**, 3-Azabicyclo[3.2.1]octane, 3-(4-amino-3,5-dibromobenzyl)-1,8,8-tri-methyl-, hydrochloride **94804-17-8**, 3-Azabicyclo[3.2.1]octane, 3-(2-amino-3,5-dibromobenzyl)-1,8,8-trimethyl- (preparation of)

RN 21782-04-7 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 3-(4-amino-2,5-dibromobenzyl)-1,8,8-trimethyl-, hydrochloride (8CI) (CA INDEX NAME)



●x HCl

RN 94804-17-8 CAPLUS

CN 3-Azabicyclo[3.2.1]octane, 3-(2-amino-3,5-dibromobenzyl)-1,8,8-trimethyl- (7CI) (CA INDEX NAME)



```
=> s guaifenesin?
L56         411 GUAIFENESIN?

=> s l47 and l56
            187 L47
L57           0 L47 AND L56

=> s l54 and l56
L58         115 L54 AND L56

=> s treat? (l) cough?
        3190436 TREAT?
           5176 COUGH?
L59        1381 TREAT? (L) COUGH?

=> s l56 and l59
L60          14 L56 AND L59

=> d l60 1-14 bib,ab
```

L60 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:49102 CAPLUS
DN 140:87653
TI Effect of **guaifenesin** on cough reflex sensitivity
AU Dicpinigaitis, Peter V.; Gayle, Yvonne E.
CS Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA
SO Chest (2003), 124(6), 2178-2181
CODEN: CHETBF; ISSN: 0012-3692
PB American College of Chest Physicians
DT Journal
LA English
AB **Guaifenesin**, a commonly used agent for the **treatment** of **cough**, is termed an expectorant since it is believed to alleviate **cough** discomfort by increasing sputum volume and decreasing its viscosity, thereby promoting effective **cough**. Despite its common usage, relatively few studies, yielding contrasting results, have been performed to investigate the action and efficacy of **guaifenesin**. The purpose of this study was to evaluate the effect of **guaifenesin** on **cough** reflex sensitivity. A randomized, double-blind, placebo-controlled trial was conducted at an an academic medical center. Fourteen subjects with acute viral upper respiratory tract infection (URI), and 14 healthy volunteers participated. On 2 sep. days, subjects underwent capsaicin **cough** challenge 1 to 2 h after receiving a single, 400-mg dose (capsules) of **guaifenesin** or matched placebo. The concentration of capsaicin inducing five or more **coughs** (C5) was determined Among subjects with URI, mean (± SEM) log C5 after **guaifenesin** and placebo were 0.92 ± 0.17 and 0.66 ± 0.14, resp. ($p = 0.028$). No effect on **cough** sensitivity was observed in healthy volunteers. Our results demonstrate that **guaifenesin** inhibits **cough** reflex sensitivity in subjects with URI, whose **cough** receptors are transiently hypersensitive, but not in healthy volunteers. Possible mechanisms include a central antitussive effect, or a peripheral effect by increased sputum volume serving as a barrier shielding **cough** receptors within the respiratory epithelium from the tussive stimulus.
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:912596 CAPLUS
DN 139:386391
TI Sustained release of **guaifenesin** combination drugs
IN Davis, Robert D.; Blume, Ralph W.; Keyser, Donald Jeffrey
PA USA
SO U.S. Pat. Appl. Publ., 95 pp., Cont.-in-part of U.S. Ser. No. 121,706.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003215508	A1	20031120	US 2003-413530	20030415
	US 6372252	B1	20020416	US 2000-559542	20000428
	US 2003049318	A1	20030313	US 2002-121706	20020415
PRAI	US 2000-559542	A2	20000428		
	US 2002-121706	A2	20020415		

AB The invention relates to a novel pharmaceutical modified release formulation of **guaifenesin** and dextromethorphan. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl Me cellulose, and a water-insol. polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight This formulation capable of providing therapeutically effective bioavailability of **guaifenesin** for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of **guaifenesin** and a second portion having a sustained release formulation of **guaifenesin**, wherein one or both portions further comprises dextromethorphan. The modified release product has a maximum **guaifenesin** serum concentration equivalent to that of an immediate release **guaifenesin** tablet, and is capable of providing therapeutically effective bioavailability of **guaifenesin** for at least twelve hours after dosing in a human subject. For example, bilayer tablets were prepared comprising (i) a sustained-release layer containing **guaifenesin** 101.00 mg, dextromethorphan HBr 4.50 mg, Carbopol 974P 1.50 mg, Methocel E10M 5.00 mg, D&C Yellow Number 10 0.04 mg, and magnesium stearate 1.00%, and (ii) an immediate release layer containing **guaifenesin** 45.60 mg, dextromethorphan HBr 3.60 mg, Explotab 3.60%, Avicel PH102 40.32 mg, Methocel E10M 2.40 mg, and magnesium stearate 0.48%.

L60 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:633408 CAPLUS
DN 139:159977
TI **Treatment** of colds and **cough** with a combination of a cyclooxygenase-2 selective inhibitor and a colds and **cough** active ingredient, and compositions thereof
IN MacMillan, Stephen P.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003065988	A2	20030814	WO 2003-US3221	20030204
	WO 2003065988	A3	20040219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2474016	AA	20030814	CA 2003-2474016	20030204
	US 2004029864	A1	20040212	US 2003-357747	20030204
	EP 1471872	A2	20041103	EP 2003-707692	20030204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007755	A	20041207	BR 2003-7755	20030204
PRAI	US 2002-354135P	P	20020204		
	WO 2003-US3221	W	20030204		

AB A method for the **treatment**, prevention and amelioration of colds and/or **cough** in a subject in need of such **treatment**, prevention and amelioration, comprises administering to the subject a cyclooxygenase-2 selective inhibitor (e.g. celecoxib; preparation given), or prodrug thereof, and one or more colds and **cough** active ingredient. Compns., pharmaceutical compns. and kits for practicing the method are also disclosed.

L60 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:241987 CAPLUS
DN 138:243343
TI Tannate compositions for treatment of upper respiratory disorders
IN Venkataraman, Balaji
PA USA
SO U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. 6,509,492.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003060422	A1	20030327	US 2002-56805	20020125
	US 6509492	B1	20030121	US 2001-952711	20010914
PRAI	US 2001-316548P	P	20010831		
	US 2001-952711	A2	20010914		

AB The present invention is directed to methods and compns. for **treating** upper respiratory indications, such as the **treatment**, management or mitigation of **cough**, cold, cold-like symptoms, symptoms related to upper respiratory infections, influenza symptoms and allergic rhinitis, perennial rhinitis, nasal and Eustachian tube congestion in an animal by administration of tannate compns. comprising single agent (amine drug tannate) formulations or combinations of at least 1 or more agents into a single administrative dose. As an example, pseudoephedrine tannate at 75-300 mg/5 mL can be used.

L60 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:807277 CAPLUS
DN 137:299959
TI Antitussives for the **treatment** of common cold **cough**
IN Okudaira, Ichiro; Ichihara, Takashi; Nakagami, Joji; Aikawa, Katsuyoshi; Nakagawa, Yasuo
PA Taisho Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2002308761	A2	20021023	JP 2001-110461	20010409
PRAI JP 2001-110461		20010409		

AB This invention relates to antitussives comprising (1) ≥ 1 compds. selected from the group consisting of codeine (or its related compds.), xanthine (or its related compds.), alloclamide, cloperastine, tipepidine, pentoxyverine, and/or salts thereof and (2) pseudoephedrine. For example, a capsule (200 mg each) contained codeine phosphate 48, noscapine 36, pseudoephedrine hydrochloride 80, chlorpheniramine maleate 12, **guaifenesin** 150, lactose 350, microcryst. cellulose 255, and Mg stearate 15 parts.

L60 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:385008 CAPLUS
DN 136:390999
TI Oral compositions containing coolants and sweeteners having improved consumer aesthetics
IN Lee, Kuo-Chung Mark
PA The Procter & Gamble Company, USA
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6391886	B1	20020521	US 2000-729406	20001204
	WO 2002045714	A1	20020613	WO 2001-US45035	20011130
	W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002039397	A5	20020618	AU 2002-39397	20011130
	EP 1339408	A1	20030903	EP 2001-987156	20011130
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004515478	T2	20040527	JP 2002-547498	20011130
PRAI	US 2000-729406	A	20001204		
	WO 2001-US45035	W	20011130		

AB Oral compns. containing therapeutic agents wherein the undesirable consumer aesthetics associated with these agents are mitigated using coolants and sweeteners. Thus, a **cough treatment** composition contained dextromethorphan 2.20. propylene glycol 42.45, Pluronic-F127 29.71, water 12.08, EtOH 10.91, sodium metabisulfite 0.10, disodium EDTA 0.10, Eucalyptus flavor 0.45, menthol 0.20 WS-3 0.15, 1-menthone-/D-isomenthone glycerin ketal (MGA) 0.30, 3-l-menthoxypropane-1,2-diol 0.10, sodium saccharin 0.60, potassium acesulfame 0.50, and monoammonium glycyrrhizinate 0.15%.

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:406245 CAPLUS
DN 135:10046
TI Pharmaceutical compositions containing dimemorfan for pharynx
IN Kitahara, Akemi; Takenaga, Takaaki
PA Taisho Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2001151677	A2	20010605	JP 1999-336433	19991126
PRAI JP 1999-336433		19991126		

AB The invention relates to a pharmaceutical composition, e.g. tablet, capsule, and liquid, for use for **treatment** of sore throat, pharyngeal inflammation caused by **coughing**, etc., wherein the pharynx composition contains (a) dimemorhan and (b) ambroxol, bromhexine, **guaifenesin**, chlorpheniramine, carbinoxamine, and/or mequitazine. Capsules were prepared from dimemorfan phosphate 30, noscapine 60, chlorpheniramine maleate 12, DL-methylephedrine hydrochloride 75, **guaifenesin** 125, caffeine anhydride 150, lactose 112, crystalline cellulose 82, and magnesium stearate 14 g.

L60 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:675272 CAPLUS
DN 132:160660
TI Effects of drugs on mucus clearance
AU Houtmeyers, E.; Gosselink, R.; Gayan-Ramirez, G.; Decramer, M.
CS Respiratory Muscle Research Unit, Laboratory of Pneumology and Respiratory Division, Faculty of Physical Education and Physiotherapy, Katholieke Universiteit Leuven, Louvain, Belg.
SO European Respiratory Journal (1999), 14(2), 452-467
CODEN: ERJOEI; ISSN: 0903-1936
PB Munksgaard International Publishers Ltd.
DT Journal; General Review
LA English
AB A review with 152 refs. Mucociliary clearance (MCC), the process in which airway mucus with substances trapped within are moved out of the lungs, is an important mechanism of the human body. Drugs may alter this process, such that it is to know the effect of the drugs on MCC. Indeed, agents stimulating MCC be used therapeutically in respiratory medicine, especially in patients suspected an impairment of their mucociliary transport system. In contrast, caution be taken with drugs depressing MCC as an undesired side-effect, of their therapeutic indication. Since **cough** clearance (CC) serves as a back-up when MCC fails, the influence of drugs must be examined not only on MCC also on CC. Ultimately, the clin. repercussions of alterations in mucus transport by drug administration must be studied. Ammonium compds. (anticholinergics), aspirin, anesthetic agents and have been shown to be capable of depressing the mucociliary system. Cholinergics, methylxanthines, sodium cromoglycate, hypertonic saline, as well as water aerosol have been shown to increase MCC. Adrenergic, **guaifenesin**, S-carboxymethylcysteine, sodium 2-mercapto-ethane and frusemide have been reported not to alter the mucociliary transport . Amiloride, UTP (UTP), quaternary ammonium (anticholinergics), adrenergic agonists, corticosteroids, recombinant human (rhDNase), N-acetylcysteine, bromhexine and ambroxol have been either not to change or to augment MCC. Indirect data suggest that as well as antibiotics may improve the mucociliary transport system. For the influence of drugs on CC, amiloride and rhDNase have been to increase the effectiveness of **cough**. A trend towards an improved CC was after **treatment** with adrenergic agonists. The anticholinergic agent ipratropium, which is a quaternary ammonium compound, has been suggested to CC significantly. Bromhexine, ambroxol and neutral saline seemed not to CC, either pos. or neg. Finally, **treatment** with either amiloride, recombinant human DNase,, ambroxol, N-acetylcysteine, S-carboxymethylcysteine or hypertonic has been suggested as a possible cause of clin. improvement in patients, such experience of dyspnea, the case of expectoration or the frequency of infective . Other agents did not show a clin. benefit.
RE.CNT 152 THERE ARE 152 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:502403 CAPLUS
DN 132:58986
TI An in vitro comparison of the mucoactive properties of **guaifenesin**, iodinated glycerol, surfactant, and albuterol
AU Rubin, Bruce K.
CS Department of Pediatrics, Wake Forest University School of Medicine, Winston-Salem, NC, USA
SO Chest (1999), 116(1), 195-200
CODEN: CHETBF; ISSN: 0012-3692
PB American College of Chest Physicians
DT Journal
LA English
AB Study objective: The mechanism of action of potential mucoactive agents could relate to effects on the mucociliary apparatus or to direct effects on the secretions. The purpose of this study was to determine the in vitro effects of several agents on the properties of mucus simulants and sputum collected from 30 adults with stable chronic bronchitis. Design: Sputum or simulants were analyzed untreated and after the addition of the test agent at 1:5 volume to volume ratio for a contact period of 60 s. The concns. of the agents were as follows: **guaifenesin**, 20 mg/mL; iodinated glycerol, 3 mg/mL; surfactant (Exosurf; Glaxo Well-come; Research Triangle Park, NC) containing 13.5 mg of phospholipid per mL; albuterol, 5 mg/mL; and amphibian Ringer's solution (ARS) as a control. Dynamic viscoelasticity and surface mech. impedance were measured in a magnetic microrheometer. Cohesiveness was measured using a filancemeter. The wettability of a hydrophilic surface was measured using an image processing system. The mucociliary transportability of sputum was timed on the frog palate, and **cough** transportability (CTR) was measured in a **cough** machine. Results: When compared to sputum that had no test agent or ARS added, all agents reduced sputum elasticity G', with surfactant, albuterol, and **guaifenesin** significant at $p < 0.001$. As well, **guaifenesin** ($p = 0.006$), albuterol ($p = 0.003$), and surfactant ($p = 0.02$) decreased surface mech. impedance (frictional adhesiveness) compared to untreated sputum. However, there were no significant changes in wettability, hydration, cohesiveness, or CTR with any agent, and there were no significant changes in the properties of sputum or simulants **treated** with test agents when compared to those **treated** with ARS. **Guaifenesin** irreversibly disrupted mucociliary transport when applied directly to the frog palate. Conclusions: These agents appear to have a minimal direct action on sputum in vitro, suggesting that at the concns. studied, these agents do not have a significant beneficial effect on either the mucociliary transportability or CTR of chronic bronchitis sputum. However, there could be an effect of some of these agents after oral administration, especially if there is a secondary effect of the agent on an effector cell.
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:425758 CAPLUS
DN 131:63456
TI Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
IN Jensen, Peder K.; Lorber, Richard R.; Danzig, Melvyn R.; Medeiros, Paul T.
PA Schering Corporation, USA
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932125	A1	19990701	WO 1998-US26223	19981221
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	ZA 9811731	A	19990621	ZA 1998-11731	19981221
	CA 2315721	AA	19990701	CA 1998-2315721	19981221
	AU 9919071	A1	19990712	AU 1999-19071	19981221
	AU 758771	B2	20030327		
	BR 9814417	A	20001010	BR 1998-14417	19981221
	EP 1041990	A1	20001011	EP 1998-963828	19981221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
	JP 2001526232	T2	20011218	JP 2000-525116	19981221
	NZ 520907	A	20040528	NZ 1998-520907	19981221
	NO 2000003288	A	20000822	NO 2000-3288	20000622
PRAI	US 1997-68638P	P	19971223		
	US 1998-78638P	P	19980319		
	NZ 1998-504832	A1	19981221		
	WO 1998-US26223	W	19981221		

AB The invention relates to a pharmaceutical composition useful in the **treatment** of sneezing, itching runny nose, nasal congestion, redness of the eye, tearing, itching of the ears or palate, shortness of breath, inflammation of the bronchial mucosa, reduced Forced Expiratory Volume In One Second (FEV1), **coughs**, rash, itchy skin, headaches, and aches and pains associated with seasonal allergic rhinitis, perennial allergic rhinitis, common colds, otitis, sinusitus, allergy, asthma, allergic asthma and/or inflammation, in a mammalian organism in need of such **treatment**. The composition comprises: (i) an effective amount of at least one leukotriene antagonist selected from (a) montelukast, (b) 1-(((R)- (3-(2-(6,7- difluoro-2- quinolinyl)ethenyl)phenyl)-3-(2-(2-hydroxy-2-propyl)phenyl)propyl) thio)methylcyclopropaneacetic acid; (c) 1-(((1(R)-3 (3-(2-(2,3- dichlorothieno[3, 2-b]pyridin-5-yl) -(E)-ethenyl)phenyl) -3-(2-(1-hydroxy-1- methylethyl) phenyl)propyl) thio)methyl) cyclopropaneacetic acid; (d) pranlukast; or (f) [2-[[2-(4-tert -butyl-2-thiazolyl) -5-benzofuranyl] oxymethyl]phenyl] acetic acid; or a pharmaceutically acceptable salt thereof; in admixt. with (ii) an effective amount of at least one antihistamine which is descarboethoxyloratidine, cetirizine, fexofenadine, ebastine, astemizole, norastemizole, epinastine, efletirizine or a pharmaceutically acceptable

salt thereof.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:776660 CAPLUS
DN 130:29242
TI Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
IN Barrett, David Michael; Jones, Huw Lyn; Jones, Idwal; Smith, Carl Simon
PA The Boots Company PLC, UK
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9852545	A1	19981126	WO 1998-EP3180	19980522
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9879167	A1	19981211	AU 1998-79167	19980522
PRAI	GB 1997-10525	A	19970522		
	GB 1997-10632	A	19970522		
	WO 1998-EP3180	W	19980522		

AB The present invention relates to pharmaceuticals comprising a combination of flurbiprofen with (a) a therapeutically effective amount of 1 or more active ingredients selected from an antihistamine, a **cough** suppressant, a decongestant, an expectorant, a muscle relaxant, a centrally acting analgesic, a local anesthetic, an antibacterial, an antiviral agent, an antibiotic, an antifungal agents, minerals and vitamins and/or (b) a burn-masking amount of an agent which has a warming effect on the mucosa of the throat for use in the **treatment** of cold and flu symptoms including particularly sore throat. The **treatment** comprises the administration of a pharmaceutical masticable or suckable solid dosage form or a liquid or spray which releases the flurbiprofen and active ingredient(s) and/or burn-masking agent in the oral cavity so as to deliver the active components to the surface of the sore throat. Thus, each lozenge contained racemic flurbiprofen 8.75, CaCO3 7.5, active ingredient (e.g., antihistamine) q.v.(quantum vis), solids from a 1:1 mixture of sugar and liquid glucose to 2350 mg.
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:776655 CAPLUS
DN 130:29238
TI Pharmaceutical compositions containing NSAIDS
IN Barrett, David Michael; Jones, Huw Lyn; Jones, Idwal; Smith, Carl Simon
PA The Boots Company PLC, UK
SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9852540	A1	19981126	WO 1998-EP3179	19980522
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9881079	A1	19981211	AU 1998-81079	19980522
PRAI	GB 1997-10505	A	19970522		
	GB 1997-10527	A	19970522		
	GB 1997-10544	A	19970522		
	WO 1998-EP3179	W	19980522		

AB The present invention relates to the use of an NSAID selected from ibuprofen, naproxen, ketoprofen, diclofenac, piroxicam and indomethacin in the **treatment** of the symptoms of cold and flu particularly sore throat. The method consists of administration to a patient of a pharmaceutical composition in the form of a masticable or suckable solid dosage form or a liquid or a spray containing a therapeutically effective amount of the NSAID which releases the NSAID in the oral cavity so as to deliver the NSAID to the surface of the sore throat. The composition may also contain (a) therapeutically effective amount of 1 or more active ingredients selected from an antihistamine, a **cough** suppressant, a decongestant, an expectorant, a muscle relaxant, a centrally acting analgesic, a local anesthetic, an antibacterial compound, an antiviral compound, an antibiotic compound, an antifungal compound, minerals and vitamins and/or (b) a burn-masking amount of an agent which has a warming effect on the mucosa of the throat. Thus, a lozenge contained CaCO3 7.5, PVP 1.43, aerosil 0.036, Mg stearate 0.18, isomalt 1885, lycasin 440 mg, ketoprofen q.v. (quantum vis) and flavoring q.v.

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L60 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:400747 CAPLUS
DN 111:747
TI Antitussive expectorant containing butamirate citrate and **guaifenesin**
IN Kubec, Frantisek; Srajer, Rajmund; Juchelka, Jiri
PA Czech.
SO Czech., 3 pp.
CODEN: CZXXA9
DT Patent
LA Czech
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CS 254358	B1	19880115	CS 1985-2862	19850418
PRAI CS 1985-2862		19850418		

AB An antitussive expectorant solution contains butamirate citrate (I) 0.05-0.5, licorice extract 0.1-0.2, **guaifenesin** (II) 1-10 weight %, aroma, propanediol, EtOH, solubilizers, and H2O. An antitussive expectorant contained I 0.40, II 10.00, licorice extract 0.30, aroma (alpine flowers) 0.20, polysorbate 80 0.10, 95% EtOH 30.00, distilled H2O 0.70, and propylene glycol to 100.00 weight%. In clin. tests against various resp. disorders (e.g. acute bronchitis, chronic bronchitis, pharyngitis, laryngitis, etc.), it had good secretomotor and mucokinetic effects (easy and copious expectoration) and improved lung ventilation.

L60 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1987:561726 CAPLUS
DN 107:161726
TI Sucrose-free pharmaceutical preparations containing fructose as sweetener for use by diabetics
PA Warner-Lambert Co., USA
SO Neth. Appl., 8 pp.
CODEN: NAXXAN
DT Patent
LA Dutch
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NL 8503539	A	19870716	NL 1985-3539	19851220
PRAI NL 1985-3539		19851220		

AB Fructose is useful as a sweetener for drug prepns. for **treatment** of e.g. **coughs** and cold symptoms in diabetics. A **cough** and cold syrup was prepared containing **guaifenesin** 1.000, diphenhydramine-HCl 0.225, Na citrate 1.000, citric acid 0.200, fructose 50 g and glycerol 6.25 mL/100 mL.

```
=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              213.10     400.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                              -32.85     -32.85

STN INTERNATIONAL LOGOFF AT 17:56:46 ON 24 MAY 2005
```